View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
	Mar. 31, 2012	Apr. 30, 2012	Oct. 01, 2011
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		25,340,448
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,387,470,924

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Net revenues	$ 727,844	$ 676,694	$ 645,430
Cost of goods sold	358,604	321,485	307,949
Gross profit	369,240	355,209	337,481
Operating expenses:
Research and development	36,801	32,656	26,376
Selling, general and administrative	245,261	213,899	214,483
Contingent consideration income	(1,580)	(1,894)	(2,345)
Asset impairment	0	0	15,686
Total operating expenses	280,482	244,661	254,200
Operating income	88,758	110,548	83,281
Other income (expense), net	740	(467)	(2,010)
Income before provision for income taxes	89,498	110,081	81,271
Provision for income taxes	22,612	30,101	22,901
Net income	$ 66,886	$ 79,980	$ 58,370
Basic income per common share
Net income (in dollars per share)	$ 2.64	$ 3.19	$ 2.29
Income per common share assuming dilution
Net income (in dollars per share)	$ 2.59	$ 3.12	$ 2.24
Weighted average shares outstanding
Basic (in shares)	25,364	25,077	25,451
Diluted (in shares)	25,795	25,596	26,063

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011
Current assets:
Cash and cash equivalents	$ 228,861	$ 196,707
Accounts receivable, less allowance of $1,480 at March 31, 2012 and $1,799 at April 2, 2011	135,464	127,166
Inventories, net	117,163	84,387
Deferred tax asset, net	9,665	9,674
Prepaid expenses and other current assets	35,976	30,897
Total current assets	527,129	448,831
Property, plant and equipment:
Land, building, and building improvements	59,816	52,359
Plant equipment and machinery	136,057	128,612
Office equipment and information technology	88,185	83,258
Haemonetics equipment	226,476	211,455
Total property, plant and equipment	510,534	475,684
Less: accumulated depreciation	(348,877)	(320,156)
Net property, plant and equipment	161,657	155,528
Other assets:
Intangible assets, less amortization of $54,973 at March 31, 2012 and $43,827 at April 2, 2011	96,549	101,789
Goodwill	115,058	115,367
Deferred tax asset, long term	23	1,291
Other long-term assets	10,719	10,458
Total other assets	222,349	228,905
Total assets	911,135	833,264
Current liabilities:
Notes payable and current maturities of long-term debt	894	913
Accounts payable	35,425	28,323
Accrued payroll and related costs	29,451	27,039
Accrued income taxes	8,075	6,033
Deferred tax liability	64	107
Other liabilities	56,835	46,256
Total current liabilities	130,744	108,671
Long-term debt, net of current maturities	2,877	3,966
Long-term deferred tax liability	23,332	18,669
Other long-term liabilities	21,551	15,822
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 25,301,899 shares at March 31, 2012 and 25,660,393 shares at April 2, 2011	253	256
Additional paid-in capital	322,485	302,709
Retained earnings	400,783	373,630
Accumulated other comprehensive income	9,110	9,541
Total stockholders' equity	732,631	686,136
Total liabilities and stockholders' equity	$ 911,135	$ 833,264

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011
Accounts receivable, allowance	$ 1,480	$ 1,799
Intangible assets, amortization	$ 54,973	$ 43,827
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	25,301,899	25,660,393
Common stock, outstanding	25,301,899	25,660,393

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY AND OTHER COMPREHENSIVE INCOME - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Comprehensive Income [Member]
Balance, value at Mar. 28, 2009	$ 539,884	$ 256	$ 226,829	$ 309,516	$ 3,283
Balance, shares (in shares) at Mar. 28, 2009		25,622,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan, value	2,909	$ 1	2,908
Employee stock purchase plan, shares (in shares)		66,000
Exercise of stock options and related tax benefit, value	19,072	$ 5	19,067
Exercise of stock options and related tax benefit, shares (in shares)		488,000
Shares repurchased, value	(40,000)	$ (7)	(6,748)	(33,245)
Shares repurchased, shares (in shares)		(735,000)
Stock compensation expense	10,267		10,267
Net income	58,370			58,370		$ 58,370
Impact of defined benefit plans, net of tax	(309)				(309)	(309)
Foreign currency translation adjustment	2,599				2,599	2,599
Unrealized gain (loss) on hedges, net of tax	(477)				(477)	(477)
Reclassification of hedge loss to earnings, net of tax	809				809	809
Comprehensive income						60,992
Balance, value at Apr. 03, 2010	593,124	$ 255	252,323	334,641	5,905
Balance, shares (in shares) at Apr. 03, 2010		25,441,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan, value	3,681	$ 1	3,680
Employee stock purchase plan, shares (in shares)		78,000
Exercise of stock options and related tax benefit, value	44,905	$ 9	44,896
Exercise of stock options and related tax benefit, shares (in shares)		1,012,000
Shares repurchased, value	(50,000)	$ (9)	(9,000)	(40,991)
Shares repurchased, shares (in shares)		(907,000)
Issuance of restricted stock, net of cancellations, shares (in shares)		36,000
Stock compensation expense	10,810		10,810
Net income	79,980			79,980		79,980
Impact of defined benefit plans, net of tax	555				555	555
Foreign currency translation adjustment	6,380				6,380	6,380
Unrealized gain (loss) on hedges, net of tax	(4,068)				(4,068)	(4,068)
Reclassification of hedge loss to earnings, net of tax	769				769	769
Comprehensive income	3,636					83,616
Balance, value at Apr. 02, 2011	686,136	$ 256	302,709	373,630	9,541
Balance, shares (in shares) at Apr. 02, 2011		25,660,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan, value	3,723	$ 1	3,722
Employee stock purchase plan, shares (in shares)		77,000
Exercise of stock options and related tax benefit, value	$ 17,028	$ 4	17,024
Exercise of stock options and related tax benefit, shares (in shares)	369,092	369,000
Shares repurchased, value	$ (49,998)	$ (9)	(10,256)	(39,733)
Shares repurchased, shares (in shares)		(852,000)
Issuance of restricted stock, net of cancellations, value	1	$ 1
Issuance of restricted stock, net of cancellations, shares (in shares)		48,000
Stock compensation expense	9,286		9,286
Net income	66,886			66,886		66,886
Impact of defined benefit plans, net of tax	(3,988)				(3,988)	(3,988)
Foreign currency translation adjustment	(2,813)				(2,813)	(2,813)
Unrealized gain (loss) on hedges, net of tax	3,140				3,140	3,140
Reclassification of hedge loss to earnings, net of tax	3,230				3,230	3,230
Comprehensive income	(431)					$ 66,455
Balance, value at Mar. 31, 2012	$ 732,631	$ 253	$ 322,485	$ 400,783	$ 9,110
Balance, shares (in shares) at Mar. 31, 2012		25,302,000

CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	12 Months Ended
	Mar. 31, 2012 USD ($)	Apr. 02, 2011 USD ($)	Apr. 03, 2010 USD ($)
Cash Flows from Operating Activities:
Net income	$ 66,886	$ 79,980	$ 58,370
Non cash items:
Depreciation and amortization	49,966	48,145	43,236
Stock compensation expense	9,286	10,810	10,267
Deferred tax expense	5,878	5,782	2,592
Loss/(gain) on sales of property, plant and equipment	772	674	(435)
Unrealized loss/(gain) from hedging activities	166	(614)	(1,368)
Contingent consideration income	(1,580)	(1,894)	(2,345)
(Reversal)/accretion of interest expense on contingent consideration	(574)	(416)	588
Asset impairment	0	0	15,686
Change in operating assets and liabilities:
(Increase)/decrease in accounts receivable, net	(10,539)	(3,920)	4,364
(Increase)/decrease in inventories	(32,528)	(2,560)	(1,665)
Decrease in prepaid income taxes	3,058	1,680	7,254
Decrease in other assets and other long-term liabilities	3,156	(470)	(13,809)
Tax benefit on exercise of stock options	1,958	4,941	2,670
Increase/(decrease) in accounts payable and accrued expenses	19,413	(18,683)	5,263
Net cash provided by operating activities	115,318	123,455	130,668
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(53,198)	(46,669)	(56,304)
Proceeds from sale of property, plant and equipment	1,002	1,468	1,785
Acquisition of ACCS	0	(6,229)	0
Acquisition of Global Med Technologies	0	(128)	(58,052)
Acquisition of SEBRA	0	0	(12,845)
Acquisition of Neoteric	0	0	(6,613)
Acquisition of Medicell	0	0	(306)
Net cash used in investing activities	(52,196)	(51,558)	(132,335)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(815)	(632)	(754)
Net (decrease)/increase in short-term loans	(288)	(15,153)	6,184
Proceeds from employee stock purchase plan	3,723	3,681	2,909
Proceeds from exercise of stock options	15,475	40,896	17,270
Excess tax benefit on exercise of stock options	1,433	3,124	421
Share repurchase	(49,998)	(50,000)	(40,000)
Net cash used in financing activities	(30,470)	(18,084)	(13,970)
Effect of exchange rates on cash and cash equivalents	(498)	1,332	478
Net increase in Cash and Cash Equivalents	32,154	55,145	(15,159)
Cash and Cash Equivalents at Beginning of Year	196,707	141,562	156,721
Cash and Cash Equivalents at End of Period	228,861	196,707	141,562
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	18,333	5,069	7,833
Debt assumed from acquisition	0	0	5,132
Supplemental Disclosures of Cash Flow Information:
Interest paid	414	487	563
Income taxes paid	$ 10,764	$ 16,669	$ 21,519

DESCRIPTION OF BUSINESS	12 Months Ended
DESCRIPTION OF BUSINESS	Mar. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF THE BUSINESS Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers — plasma collectors, blood collectors, and hospitals. Anchored by our strong brand name in medical device systems for the transfusion industry, we also provide information technology platforms and valued added services to provide customers with business solutions which support improved clinical outcomes for patients and efficiency in the blood supply chain. Our systems automate the collection and processing of donated blood; perform blood diagnostics; salvage and process surgical patient blood; and dispense blood within the hospital. These systems include devices and single-use, proprietary disposable sets that operate only on our specialized equipment. Our blood processing systems allow users to collect and process only the blood component(s) they target — plasma, platelets, or red blood cells — increasing donor and patient safety as well as collection efficiencies. Our blood diagnostics system assesses the likelihood of a patient’s blood loss allowing clinicians to make informed decisions about a patient’s treatment as it relates to blood loss in surgery. Our surgical blood salvage systems collect blood lost by a patient in surgery, clean the blood, and make it available for reinfusion to the patient, in this way giving the patient the safest blood possible — his or her own. Our blood distribution systems are “smart” refrigerators located throughout hospitals which automate the storage, inventory tracking, and dispositioning of blood in key blood use areas. Our information technology platforms are used by blood and plasma collectors to improve the safety and efficiency of blood collection logistics by eliminating previously manual functions at not-for-profit blood centers and commercial plasma centers. Our platforms are also used by hospitals to enable hospital administrators to monitor and measure blood management practices and to manage processes within transfusion services. Our information technology platforms allow all customers to better manage processes across the blood supply chain, comply with regulatory requirements, and identify increased opportunities to reduce costs. Our business services include consulting, Six Sigma, and LEAN manufacturing offerings that support our customers’ needs for regulatory compliance and operational efficiency in the blood supply chain and best practice in blood management.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Name Statement of Position (SOP)
-Publisher AICPA
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Name FASB Interpretation (FIN)
-Publisher FASB
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

12 Months Ended

Mar. 31, 2012

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year

Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2012 and 2011 each includes 52 weeks with each quarter having 13 weeks. Fiscal year 2010 includes 53 weeks with each of the first three quarters having 13 weeks and the fourth quarter having 14 weeks.

Principles of Consolidation

The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions.

Reclassifications

Certain reclassifications have been made to prior years’ amounts to conform to the current year’s presentation.

Revenue Recognition

Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition, and ASC Topic 985-605, Software. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software, we establish fair value of undelivered elements based upon vendor specific objective evidence.

Product Revenues

Product sales consist of the sale of our equipment devices and the related disposables used with these devices. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. All shipments to distributors are at contract prices and payment is not contingent upon resale of the product.

Collection of Taxes from Customers

We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority.

Software Solutions and Services Revenues

Our software solutions business provides support to our plasma and blood collection customers and hospitals. Through our Haemonetics Software Solutions unit, we provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities.

Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. With the acquisition of Global Med, a significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees.

We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.

Translation of Foreign Currencies

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from inter-company transactions, are included in other income, net on the consolidated statements of income.

Cash and Cash Equivalents

Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 31, 2012, our cash and cash equivalents consisted of investments in United States Government Agency and Institutional Money Market Funds.

Allowance for Doubtful Accounts

We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables. We establish allowances for balances not yet due and past due accounts based on past experience.

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society, amounted to $99.5 million, $95.9 million, and $92.6 million for 2012, 2011, and 2010, respectively. Accounts receivable balances attributable to this customer accounted for 15.3%, 13.7%, and 12.6% of our consolidated accounts receivable at fiscal year ended 2012, 2011, and 2010. Sales to another global healthcare customer, "Customer B", amounted to $79.9 million in fiscal 2012. Accounts receivable balances attributable to this customer accounted for 6.6% of our consolidated accounts receivable at fiscal year ended 2012. While the accounts receivable related to the Japanese Red Cross Society and Customer B may be significant, we do not believe the credit loss risk to be significant given the consistent payment history by these customers.

Certain other markets and industries can expose us to concentrations of credit risk. For example, in our commercial plasma business, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these commercial plasma customers can be somewhat significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Deteriorating credit and economic conditions in parts of Western Europe, particularly in Italy where our net accounts receivable was $21.0 million as of March 31, 2012 and $20.4 million as of April 2, 2011, may increase the average length of time it takes us to collect our accounts receivable in certain regions within these countries.

Property, Plant and Equipment

Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:



Asset Classification		Estimated Useful Lives
Building		30 Years
Building improvements		5-20 Years
Leasehold improvements		5 Years
Plant equipment and machinery		3-10 Years
Office equipment and information technology		3-9 Years
Haemonetics equipment		2-6 Years

Depreciation expense was $38.6 million, $37.0 million, and $35.5 million for fiscal 2012, 2011, and 2010, respectively.

Leasehold improvements are amortized over the lesser of their useful lives or the term of the lease. Maintenance and repairs are expensed to operations as incurred. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income. Fully depreciated assets are removed from the accounts when they are no longer in use.

Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet entitled Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following:


•	Purchase and consumption of a certain level of disposable products


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Consistent with the impairment tests noted for other intangible assets subject to amortization, we review our property, plant, and equipment assets, subject to depreciation, and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for these devices. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results. There were no indicators of impairment in either fiscal 2012 or 2011. Expenditures for normal maintenance and repairs are charged to expense as incurred.

Goodwill and Other Intangible Assets

Intangible assets acquired in a business combination, including licensed technology, are recorded under the purchase method of accounting at their estimated fair values at the date of acquisition. Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. We amortize our other intangible assets over their useful lives using the estimated economic benefit method, as applicable.

Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles — Goodwill and Other. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. The test is based on a discounted cash flow analysis for each reporting unit. The test showed no evidence of impairment to our goodwill for either fiscal 2012, 2011 or 2010 and demonstrated that the fair value of each reporting unit significantly exceeded the reporting unit’s carrying value in each period.

We review our intangible assets, subject to amortization, and their related useful lives periodically to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. Our review includes examination of whether certain conditions exist, including: a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the market place including changes in the prices paid for our products or changes in the size of the market for our products.

An impairment loss results if the carrying value of the asset exceeds the estimated fair value of the asset. Fair value is determined using different methodologies depending upon the nature of the underlying asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

ASC Topic 985-20, Software, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed.

We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.

At the end of fiscal 2010, based on a review of ongoing development plans for our next generation platelet apheresis products (Portico), we abandoned and wrote off $12.2 million associated with previously capitalized software development costs. Additionally, in connection with the acquisition of Global Med we elected to no longer market the Symphony blood center donation management system in favor of Global Med’s El Dorado application. As a result, we wrote off the carrying value of the Symphony intangible asset totaling approximately $3.5 million.

Other Liabilities

Other liabilities represent items payable within the next twelve months. Other liabilities were $56.8 million and $46.3 million as of March 31, 2012 and April 2, 2011, respectively.

The significant items included in the fiscal year end balances were:



(In thousands)	March 31, 2012		April 2, 2011
VAT Liabilities	$	6,875	$	11,867
Forward Contracts	1,185		4,174
Deferred Revenue	24,132		21,740
HS Core Liability	3,654		—
All Other	20,989		8,475
Total	$	56,835	$	46,256

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statement of income. Advertising expenses were $4.5 million, $2.8 million, and $1.6 million for 2012, 2011 and 2010, respectively.

Accounting for Shipping and Handling Costs

Shipping and handling costs are included in costs of goods sold with the exception of $10.9 million for fiscal 2012, $9.7 million for fiscal 2011, and $11.2 million for fiscal 2010 that are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.

Income Taxes

The income tax provision is calculated for all jurisdictions in which we operate. This process involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. Deferred tax assets are periodically evaluated to determine their recoverability and a valuation allowance is established with a corresponding additional income tax provision recorded in our consolidated statements of income if their recovery is not considered more likely than not. The provision for income taxes could also be materially impacted if actual taxes due differ from our earlier estimates.

We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Uncertain tax positions are unrecognized tax benefits for which reserves have been established. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities’ full knowledge of the position and all relevant facts.

We file income tax returns in all jurisdictions in which we operate. We establish reserves to provide for additional income taxes that may be due in future years as these previously filed tax returns are audited. These reserves have been established based on management’s assessment as to the potential exposure attributable to permanent differences and interest applicable to both permanent and temporary differences. All tax reserves are analyzed periodically and adjustments are made as events occur that warrant modification.

Foreign Currency

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with ASC Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.

The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship. The gains or losses on the forward exchange contracts designated as hedges are recorded in net revenues, cost of goods sold, and operating expenses in our consolidated statements of income when the underlying hedged transaction affects earnings. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. The Company recorded foreign currency losses of $0.4 million, $1.4 million, and $2.2 million in fiscal 2012, 2011 and 2010, respectively.

Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.

Stock-Based Compensation

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of our stock options. The following assumptions, which involve the use of judgment by management, are used in the computation of the grant-date fair value of our stock options:

Expected Volatility — We have principally used our historical volatility as a basis to estimate expected volatility in our valuation of stock options.

Expected Term — We estimate the expected term of our options using historical exercise and forfeiture data. We believe that this historical data is currently the best estimate of the expected term of our new option grants.

Additionally, after determining the fair value of our stock options, we use judgment in establishing an estimated forfeiture rate, to determine the amount of stock based compensation to record each period:

Estimated Forfeiture Rate — We have applied, based on an analysis of our historical forfeitures, an annual forfeiture rate which represents the portion that we expect will be forfeited each year over the vesting period. We reevaluate this analysis periodically and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Valuation of Acquisitions

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The use of alternative valuation assumptions, including estimated cash flows and discount rates, and alternative estimated useful life assumptions could result in different purchase price allocations and intangible asset amortization expense in current and future periods.

In certain acquisitions, we have earn-out arrangements or contingent consideration to provide potential future payments to the seller for achieving certain agreed-upon financial targets. We record the contingent consideration at its fair value at the acquisition date. Generally, we have entered into arrangements with contingent consideration that require payments in cash. As such, each quarter, we revalue the contingent consideration obligations associated with certain acquisitions to their then fair value and record the change in the fair value as contingent consideration income or expense. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in assumed discount periods and rates, changes in the assumed timing and amount of revenue and expense estimates, and changes in assumed probability adjustments with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration income or expense we record in any given period.

Recent Accounting Pronouncements

In June 2011, the FASB issued Accounting Standards Update No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Update No. 2011-05 updates the disclosure requirements for comprehensive income to include total comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The updated guidance does not affect how earnings per share is calculated or presented. The updated guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, and should be applied retrospectively. Early adoption is permitted and amendments do not require any transition disclosures. We will adopt this standard in the first quarter of fiscal 2013. The adoption of ASU 2011-05 will affect the presentation of comprehensive income but will not impact our financial condition or statement of operations.

In September 2011, the FASB issued Accounting Standards Update No. 2011-08, Intangibles — Goodwill and Other (Topic 350). ASU 2011-08 allows entities to first assess qualitatively whether it is necessary to perform the two-step goodwill impairment test. If an entity believes, as a result of its qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the quantitative two-step goodwill impairment test is required. An entity has the unconditional option to bypass the qualitative assessment and proceed directly to performing the first step of the goodwill impairment test. ASU 2011-08 is effective for our first quarter of fiscal 2013 but is eligible for early adoption. We do not believe adoption of this standard will have an impact on our consolidated financial statements.

In December 2011, the FASB issued Accounting Standards Update No. 2011-11, Balance Sheet (Topic 210)-Disclosures about Offsetting Assets and Liabilities (ASU 2011-11). The update requires entities to disclose information about offsetting and related arrangements of financial instruments and derivative instruments. ASU 2011-11 is effective for our first quarter of fiscal 2014. We are currently evaluating the impact of adopting ASU 2011-11, but currently believe there will be no significant impact on our consolidated financial statements.

Standards Implemented

In October 2009, the FASB issued Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements, and Accounting Standards Update No. 2009-14, Software (Topic 985): Certain Revenue Arrangements That Include Software (the “Updates”). The Updates provide guidance on arrangements that include software elements, including tangible products that have software components that are essential to the functionality of the tangible product and will no longer be within the scope of the software revenue recognition guidance, and software-enabled products that will now be subject to other relevant revenue recognition guidance. The Updates also provide authoritative guidance on revenue arrangements with multiple deliverables that are outside the scope of the software revenue recognition guidance. Under the new guidance, when vendor specific objective evidence or third party evidence of fair value for deliverables in an arrangement cannot be determined, a best estimate of the selling price is required to allocate arrangement consideration using the relative selling price method. The Updates also include new disclosure requirements on how the application of the relative selling price method affects the timing and amount of revenue recognition. On April 3, 2011, we adopted this guidance, which did not have a material impact on our financial position and results of operations.

In December 2010, the FASB issued Accounting Standards Update No. 2010-29, Business Combinations (Topic 805): Disclosure of Supplementary Pro Forma Information for Business Combinations. Update No. 2010-29 clarifies paragraph 805-10-50-2(h) to require public entities that enter into business combinations that are material on an individual or aggregate basis to disclose pro forma information for such business combinations that occurred in the current reporting period, including pro forma revenue and earnings of the combined entity as though the acquisition date had been as of the beginning of the comparable prior annual reporting period only. We did not complete any material business acquisitions during fiscal 2012 and thus the disclosure requirements were not applicable for the period.

In May 2011, the FASB issued Accounting Standards Update No. 2011-04, Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. Update No. 2011-04 updates the accounting guidance related to fair value measurements that results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between U.S. GAAP and International Financial Reporting Standards (IFRS). ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for level 3 fair value measurements. On January 1, 2012, we adopted this guidance, which did not have a material impact on our financial position or results of operations.

ACQUISITIONS

12 Months Ended

Mar. 31, 2012

Business Combinations [Abstract]

ACQUISITIONS

During fiscal 2011 and 2010 we completed several acquisitions as part of our growth initiatives. We did not complete any acquisitions during fiscal 2012.

Fiscal 2011 Acquisition

ACCS Acquisition

On December 28, 2010, Haemonetics acquired certain assets of Applied Critical Care Services, Inc. (ACCS) for $6.4 million. ACCS was a manufacturer’s representative for Haemonetics engaged in the selling and servicing of the TEG analyzer product line. The purchase price was allocated to customer relationships of $4.5 million, other liabilities of $0.8 million, and goodwill of $2.7 million.

Fiscal 2010 Acquisitions

Global Med Acquisition

On March 31, 2010 the Company completed its cash tender offer for the shares of Global Med Technologies, Inc. (“Global Med”). The total acquisition cost for the shares and outstanding warrants of Global Med was approximately $60.4 million.

Goodwill was determined by comparing the purchase price with the fair value of the assets and liabilities acquired. The carrying value of the related goodwill has been adjusted to reflect the final purchase price allocation. At March 31, 2012, goodwill recorded after our final purchase price allocation was $39.6 million and is not tax deductible. Global Med has an in-place workforce with extensive knowledge and experience in the development and support of blood management software. The acquisition was a unique strategic fit for the Company given our global presence and customer relationships in blood management.

Purchase Price Allocation

The following chart summarizes the final purchase price allocation:



	(In thousands)
Goodwill	$	39,554
Intangible assets subject to amortization	39,920
Trade accounts receivable	6,848
Other assets	7,639
Deferred taxes	(10,928		)
Notes payable	(7,701		)
Deferred revenue	(7,180		)
Other liabilities	(7,725		)
Total	$	60,427

SEBRA Acquisition

On September 4, 2009, Haemonetics acquired the assets of the blood collection and processing business unit (“SEBRA”) of Engineering and Research Associates, Inc., a leading provider of blood and medical manufacturing technologies. SEBRA products, which include tubing sealers, blood shakers, sterile connection systems, mobile lounges and ancillary products used in blood collection and processing, complement Haemonetics’ portfolio and add depth to Haemonetics’ blood center and plasma product lines. The purchase price of $12.8 million was allocated to core technology of $2.0 million, customer relationships of $4.6 million, trade name intangible of $0.4 million, trade accounts receivables of $1.0 million, inventory of $1.1 million, and goodwill of $3.7 million.

Neoteric Acquisition

On April 16, 2009, Haemonetics acquired the outstanding shares of Neoteric. Neoteric is a medical information management company that markets a full end-to-end suite of products to track, allocate, release, and dispense hospital blood units while controlling inventory and recording the disposition of blood. The acquisition strategically broadened Haemonetics’ blood management solutions. The purchase price of $6.6 million plus contingent consideration of $5.0 million was allocated to other intangible assets of $5.0 million, deferred tax liabilities of $1.6 million, and goodwill of $8.2 million.

The contingent consideration was based upon estimated annual revenue growth for the three years following the acquisition, at established profitability thresholds, and was not limited. Using projected revenues for fiscal years 2011, 2012, and 2013, an analysis was performed that probability weighted three performance outcomes for the noted years. The performance outcomes were then discounted using a discount rate commensurate with the risks associated with Neoteric to arrive at the fair value of the contingent consideration. The Company was required to reassess the fair value of contingent consideration on a periodic basis. During fiscal 2012, 2011 and 2010, this business did not achieve the necessary revenue growth milestones for the former shareholders to receive additional performance payments. As such, we reduced the contingent liability by $1.6 million, $1.9 million and $2.3 million during fiscal 2012, 2011 and 2010, respectively, and recorded the adjustments as contingent consideration income in the consolidated statements of income. Interest expense accretion on the contingent consideration was $0.6 million in fiscal 2010, and interest expense reversal was $0.6 million and $0.4 million in fiscal 2012 and 2011, respectively.

In September 2011, we entered into an agreement to release the Company from the contingent consideration due to the former shareholders of Neoteric. Under the terms of the agreement, the former shareholders of Neoteric received $0.7 million in exchange for releasing the Company from any future claims for contingent consideration. The Company paid the $0.7 million settlement amount during September 2011 and has recorded the associated expense in the selling, general and administrative line item in the accompanying consolidated statements of income.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Appendix F
-Paragraph F4
-Subparagraph e

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1490-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1524-128463

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1392-128463

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1497-128463

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1486-128463

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1383-128463

+ Details

PRODUCT WARRANTIES

12 Months Ended

Mar. 31, 2012

Product Warranties [Abstract]

PRODUCT WARRANTIES

We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	March 31, 2012			April 2, 2011
Warranty accrual as of the beginning of the period	$	1,273		$	903
Warranty provision	2,430			1,823
Warranty spending	(2,907		)	(1,453		)
Warranty accrual as of the end of the period	$	796		$	1,273

INVENTORIES

12 Months Ended

Mar. 31, 2012

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.



(In thousands)	March 31, 2012		April 2, 2011
Raw materials	$	41,219	$	26,404
Work-in-process	4,640		4,352
Finished goods	71,304		53,631
	$	117,163	$	84,387

GOODWILL AND OTHER INTANGIBLE ASSETS

12 Months Ended

Mar. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for fiscal 2012 and 2011 are as follows:



	(In thousands)
Carrying amount as of April 3, 2010	$	109,988
SEBRA (a)	163
Altivation Software Inc.	228
ACCS (b)	2,662
Effect of change in foreign currency exchange rates	2,326
Carrying amount as of April 2, 2011	$	115,367
Effect of change in foreign currency exchange rates	(309		)
Carrying amount as of March 31, 2012	$	115,058

_______________________________________


(a)	See Note 3, Acquisitions, for a full description of the acquisition of the SEBRA^® assets, which occurred on September 4, 2009.


(b)	See Note 3, Acquisitions, for a full description of the acquisition of Applied Critical Care Services, Inc. (“ACCS”), which occurred on December 28, 2010.

Other Intangible Assets

Other intangible assets include the value assigned to license rights and other technology, patents, customer contracts and relationships, software technology, and a trade name. The estimated useful lives for all of these intangible assets are 5 to 20 years.

Aggregate amortization expense for amortized other intangible assets for fiscal year 2012, 2011, and 2010 was $11.4 million, $11.1 million, and $7.7 million, respectively. Future annual amortization expense on other intangible assets is expected to approximate $11.0 million for fiscal year 2013, $10.7 million for fiscal year 2014, $10.1 million for fiscal year 2015, $9.7 million for fiscal year 2016 and $9.4 million for fiscal year 2017.

Amortized Intangibles



	Gross Carrying Amount		Accumulated Amortization		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In years)
As of March 31, 2012
Patents	$	13,463	$	7,843	11
Capitalized software	20,597		1,394		6
Other technology	42,693		20,120		11
Customer contracts and related relationships	69,361		23,639		12
Trade names	5,408		1,977		10
Total intangibles	$	151,522	$	54,973	11



	Gross Carrying Amount		Accumulated Amortization		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In years)
As of April 2, 2011
Patents	$	12,704	$	6,827	11
Capitalized software	14,506		656		6
Other technology	43,244		17,391		11
Customer contracts and related relationships	69,908		17,740		12
Trade names	5,254		1,213		10
Total intangibles	$	145,616	$	43,827	11

The changes to the net carrying value of our intangible assets from April 2, 2011 to March 31, 2012 reflect amortization expense and the effect of exchange rate changes in the translation of our intangible assets held by our international subsidiaries.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

DERIVATIVES AND FAIR VALUE MEASUREMENTS

12 Months Ended

Mar. 31, 2012

Derivatives and Fair Value Measurements [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. For the fiscal year ended March 31, 2012, approximately 51.6% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency. Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. dollar, our reporting currency.

We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize forward foreign currency contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, British Pound Sterling and the Canadian Dollar. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of March 31, 2012 and April 2, 2011 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income in the Statement of Stockholders’ Equity until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $162.1 million as of March 31, 2012 and $154.8 million as of April 2, 2011.

During fiscal 2012 and 2011, we recognized net losses of $3.2 million and $0.8 million, respectively, in earnings on our cash flow hedges. All currency cash flow hedges outstanding as of March 31, 2012 mature within twelve months. For the fiscal year ended March 31, 2012, $3.1 million of gains, net of tax, were recorded in Other Comprehensive Income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net losses of $4.1 million for the fiscal year ended April 2, 2011. At March 31, 2012, gains of $3.1 million, net of tax, may be reclassified to earnings within the next twelve months.

Non-designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $45.5 million as of March 31, 2012 and $45.9 million as of April 2, 2011.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statement of income for the fiscal year ended March 31, 2012.



Derivative Instruments (In thousands)	Amount of Gain/(Loss) Recognized in OCI (Effective Portion)		Amount of Loss Reclassified from OCI into Earnings (Effective Portion)			Location in Statement of Operations	Amount of Gain/(Loss) Excluded from Effectiveness Testing (*)			Location in Statement of Operations
Designated foreign currency hedge contracts	$	3,140	$	(3,230	)	Net revenues, COGS, and SG&A	$	67		Other income (expense), net
Non-designated foreign currency contracts							$	(1,666	)	Other income (expense), net
	$	3,140	$	(3,230	)		$	(1,599	)

_______________________________________



(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

We did not have fair value hedges or net investment hedges outstanding as of March 31, 2012 or April 2, 2011.

ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of March 31, 2012, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of March 31, 2012 and April 2, 2011 by type of contract and whether it is a qualifying hedge under ASC Topic 815.



(In thousands)	Location in Balance Sheet	Balance as of March 31, 2012		Balance as of April 2, 2011
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	6,186	$	2,563
		$	6,186	$	2,563
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,185	$	4,174
		$	1,185	$	4,174

Other Fair Value Measurements

ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the fiscal year ended March 31, 2012 and April 2, 2011, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.

On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency derivative contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.

ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with ASC Topic 815, Derivatives and Hedging. We determine the fair value of these instruments using the framework prescribed by ASC Topic 820 by considering the estimated amount we would receive or pay to terminate these agreements at the reporting date and by taking into account current spot rates, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. We have classified our foreign currency hedge contracts within Level 2 of the fair value hierarchy because these observable inputs are available for substantially the full term of our derivative instruments. The fair value of our foreign currency hedge contracts is the estimated amount that the Company would receive or pay upon liquidation of the contracts, taking into account the change in currency exchange rates.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 31, 2012:



(In thousands)	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Money market funds	$	194,574	$	—	$	—	$	194,574
Forward currency exchange contracts	—		6,186		—		6,186
	$	194,574	$	6,186	$	—	$	200,760
Liabilities
Forward currency exchange contracts	$	—	$	1,185	$	—	$	1,185
Other liabilities — contingent consideration	—		—		—		—
	$	—	$	1,185	$	—	$	1,185

Neoteric contingent consideration

Under ASC Topic 805, Business Combinations, we established a liability for payments to former shareholders of Neoteric which were contingent on the performance of the Blood Track business in the first three years post acquisition, beginning with fiscal 2010. As of April 2, 2011, the liability was $2.3 million. We have reviewed the expected performance versus the performance thresholds for payment. Because the expected performance thresholds would not be achieved, we recorded an adjustment to the fair value of the contingent consideration liability. This appears as contingent consideration income of $1.6 million in the accompanying consolidated statements of income. Interest expense reversal on the contingent consideration was $0.6 million in fiscal 2012.

Other Fair Value Disclosures

The fair value of our real estate mortgage obligation was $3.1 million and $4.1 million at March 31, 2012 and April 2, 2011, respectively. This liability is a Level 2 financial instrument and the fair value has been determined using a net present value calculation of the future mortgage payments due discounted by a rate derived from corresponding U.S. Treasury rates.

INCOME TAXES

12 Months Ended

Mar. 31, 2012

Income Tax Disclosure [Abstract]

INCOME TAXES

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	March 31, 2012		April 2, 2011		April 3, 2010
Domestic	$	40,666	$	58,040	$	42,260
Foreign	$	48,832	$	52,041	$	39,011
Total	$	89,498	$	110,081	$	81,271

The income tax provision contains the following components:



(In thousands)	March 31, 2012			April 2, 2011		April 3, 2010
Current
Federal	$	8,505		$	14,982	$	10,088
State	2,275			2,111		887
Foreign	5,954			7,226		9,334
Total current	$	16,734		$	24,319	$	20,309
Deferred
Federal	7,522			4,931		4,103
State	(597		)	438		259
Foreign	(1,047		)	413		(1,770		)
Total deferred	$	5,878		$	5,782	$	2,592
Total	$	22,612		$	30,101	$	22,901

Included in the federal income tax provisions for fiscal 2012, 2011 and 2010 are approximately $1.6 million, $10.8 million and $8.1 million, respectively, provided on foreign source income of approximately $6.2 million, $31.0 million and $23.2 million for fiscal 2012, 2011 and 2010, respectively, for taxes which are payable in the United States.

Tax affected, significant temporary differences comprising the net deferred tax assets/(liabilities) are as follows:



(In thousands)	March 31, 2012			April 2, 2011
Depreciation	$	(17,208	)	$	(9,447	)
Amortization	(19,249		)	(20,597		)
Inventory	4,224			2,244
Hedging	(589		)	1,120
Accruals and reserves	6,352			5,950
Net operating loss carry-forward	3,354			7,241
Stock Based Compensation	8,649			7,725
Tax credit carry-forward, net	2,328			1,583
Gross Deferred Taxes	(12,139		)	(4,181		)
Less valuation allowance	$	(1,569	)	$	(3,630	)
Net deferred tax liabilities	$	(13,708	)	$	(7,811	)

As of March 31, 2012, the Company has approximately $4.7 million in U.S. acquisition and approximately $1.2 million in French acquisition related net operating loss carry-forwards that it believes are more likely than not that they will be realized. The Company also has $2.3 million in gross federal and state tax credits available to offset future tax. The Company has established valuation allowances to reduce the value of tax assets to amounts that it deems to be realizable. The valuation allowance is made up of $0.4 million acquisition-related R&D credits and $1.2 million acquisition-related net operating losses. The net operating loss carry-forwards are subject to separate limitations and will expire beginning in 2020.

Approximately $167 million of our foreign subsidiary undistributed earnings are deemed to be indefinitely reinvested outside the US. Determination of the amount of unrecognized deferred U.S. income taxes is not practical because of the complexities associated with this hypothetical calculation. Accordingly we have not provided U.S. income taxes on these earnings. The income tax provision from operations differs from tax provision computed at the 35% U.S. federal statutory income tax rate due to the following:



(In thousands)	March 31, 2012					April 2, 2011					April 3, 2010

Tax at federal statutory rate	$	31,324		35.0	%	$	38,528		35.0	%	$	28,444		35.0	%
Domestic Manufacturing Deduction	(700		)	(0.8	)%	(1,120		)	(1.0	)%	(883		)	(1.1	)%
Difference between U.S. and foreign tax	(8,539		)	(9.5	)%	(8,610		)	(7.9	)%	(4,392		)	(5.4	)%
State income taxes net of federal benefit	1,136			1.3	%	1,741			1.6	%	764			0.9	%
Repatriation of Earnings	—			—	%	(506		)	(0.5	)%	(1,574		)	(1.9	)%
Other, net	(609		)	(0.7	)%	68			0.1	%	542			0.7	%
Income tax provision	$	22,612		25.3	%	$	30,101		27.3	%	$	22,901		28.2	%

Unrecognized Tax Benefits

Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of March 31, 2012, we had $6.9 million of unrecognized tax benefits, of which $6.6 million will impact the effective tax rate, if recognized. As of April 2, 2011, we had $4.7 million of unrecognized tax benefits, of which $4.3 million will impact the effective tax rate, if recognized.

During the fiscal year ended March 31, 2012 our unrecognized tax benefits were increased by $2.1 million as a result of additional tax benefits arising in the prior year return and current year provision from the usage of acquired net operating losses with a valuation allowance recorded. This was in addition to reserves set up for other various tax matters in the amount of $0.2 million.

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ending April 2, 2011 and March 31, 2012:



(In thousands)	March 31, 2012			April 2, 2011
Beginning Balance	$	4,669		$	4,620
Additions based upon positions related to the current year	1,124			20
Additions for tax positions of prior years	1,216			1,641
Reductions of tax positions	(124		)	(1,042		)
Settlements with taxing authorities	—			—
Closure of statute of limitations	—			(570		)
Ending Balance	$	6,885		$	4,669

As of March 31, 2012 we anticipate that the liability for unrecognized tax benefits for uncertain tax positions could change by up to $0.8 million in the next twelve months, as a result of closure of various foreign statutes of limitations.

Our historic practice has been and continues to be to recognize interest and penalties related to Federal, state and foreign income tax matters in income tax expense. Approximately $1.0 million and $0.7 million was accrued for interest and penalties at March 31, 2012 and April 2, 2011, respectively and is not included in the amounts above.

We conduct business globally and, as a result, file consolidated and separate Federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. With few exceptions, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2008.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

NOTES PAYABLE AND LONG-TERM DEBT

12 Months Ended

Mar. 31, 2012

Notes Payable and Long-Term Debt [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:



(In thousands)	March 31, 2012		April 2, 2011
Real estate mortgage	$	3,771	$	4,590
Short-term notes payable	—		289
	$	3,771	$	4,879
Less-Current portion	$	894	$	913
	$	2,877	$	3,966

Real Estate Mortgage Agreement

In December 2000, we entered into a $10.0 million real estate mortgage agreement (the “Mortgage Agreement”) with an investment firm. The Mortgage Agreement requires principal and interest payments of $0.1 million per month for a period of 180 months, commencing February 1, 2001. The entire balance of the loan may be repaid at any time after February 1, 2006, subject to a prepayment premium, which is calculated based upon the change in the current weekly average yield of Ten (10)-year U.S. Treasury Constant Maturities, the principal balance due and the remaining loan term. The Mortgage Agreement provides for interest to accrue on the unpaid principal balance at a rate of 8.41% per annum. Borrowings under the Mortgage Agreement, with a carrying value of approximately $3.8 million and $4.6 million as of March 31, 2012 and April 2, 2011, respectively, are secured by the land, building and building improvements at our headquarters and manufacturing facility in the U.S.. There are no financial covenants in the terms and conditions of this agreement.

As of March 31, 2012, notes payable and long-term debt matures as follows (in thousands):



Fiscal Year Ending
2013	$	894
2014	971
2015	1,056
2016	850
2017 and thereafter	—
	$	3,771

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Mar. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

We lease facilities and certain equipment under operating leases expiring at various dates through fiscal 2017. Facility leases require us to pay certain insurance expenses, maintenance costs and real estate taxes.

Approximate future basic rental commitments under operating leases as of March 31, 2012 are as follows (in thousands):



Fiscal Year Ending
2013	$	6,169
2014	4,093
2015	2,718
2016	2,320
2017	1,852
Thereafter	2,456
	$	19,608

Rent expense in fiscal 2012, 2011, and 2010 was $6.1 million, $6.6 million, and $5.9 million, respectively.

During the first quarter of fiscal 2012, we received customer complaints in Europe regarding a quality issue with our High Separation Core Bowl (“HS Core”), a plasma disposable product used primarily to collect plasma for transfusion. Certain of these customers also made subsequent claims regarding financial losses alleged to have been incurred as a result of this matter. As of March 31, 2012, our current best estimate of the liability associated with this matter is $10.0 million, and we recorded that amount as an expense within selling, general and administrative expenses. To date, we have been reimbursed under our insurance policies for $3.7 million paid to customers to settle their claims. We have also determined that an additional $3.2 million is recoverable under our insurance policies and recorded a corresponding insurance receivable within current assets as of March 31, 2012. Receivables for insurance recoveries for product liability claims are recorded as assets, on an undiscounted basis, when it is probable that a recovery will be realized on a claim by claim basis. We have recorded $3.1 million of expenses, net of insurance recovery, within selling, general and administrative expenses for fiscal 2012 related to this matter.

We are presently engaged in various legal actions, and although our ultimate liability cannot be determined at the present time, we believe that any such liability will not materially affect our consolidated financial position or our results of operations.

For the past five years, we have pursued patent infringement lawsuits against Fenwal Inc. seeking an injunction and damages from their infringement of a Haemonetics patent, through the sale of the ALYX brand automated red cell collection system, a competitor of our automated red cell collection systems.

Currently, we are pursuing a patent infringement action in Germany against Fenwal, and its European and German subsidiary. On September 20, 2010, we filed a patent infringement action in Germany. In response, Fenwal filed an action to invalidate the Haemonetics patent which is the subject of this infringement action on December 1, 2010.

In April 2008, our subsidiary Haemonetics Italia, Srl. and two of its employees were found guilty by a court in Milan, Italy of charges arising from allegedly improper payments made under a consulting contract with a local physician and in pricing products under a tender from a public hospital. The two employees found guilty in this matter are no longer employed by the Company. On June 14, 2011, the final level appeals court affirmed these verdicts. There are no further appeals available and the convictions are now final. In connection with this conviction, our Italian subsidiary is liable to pay a fine of €147,500 and a proportionate share of the cost of the proceedings. The final amount has not yet been determined.

When this matter first arose, our Board of Directors commissioned independent legal counsel to conduct investigations on its behalf. Based upon its evaluation of counsel's report, the Board concluded that no disciplinary action was warranted in either case. Neither the original ruling nor its final affirmation has impacted the Company's business in Italy to date.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

CAPITAL STOCK

12 Months Ended

Mar. 31, 2012

Capital Stock [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

CAPITAL STOCK

Stock Plans

The Company has an incentive compensation plan, (the “2005 Incentive Compensation Plan”). The 2005 Incentive Compensation Plan permits the award of nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares to the Company’s key employees, officers and directors. The 2005 Incentive Compensation Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”) consisting of three independent members of our Board of Directors. The maximum number of shares available for award under the 2005 Incentive Compensation Plan is 7,512,460. The maximum number of shares that may be issued pursuant to incentive stock options may not exceed 500,000. Any shares that are subject to the award of stock options shall be counted against this limit as one (1) share for every one (1) share issued. Any shares that are subject to awards other than stock options shall be counted against this limit as 3.26 shares for every one (1) share granted. The exercise price for the nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares granted under the 2005 Incentive Compensation Plan is determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Options, Restricted Stock Awards and Restricted Stock Units become exercisable, or in the case of restricted stock, the resale restrictions are released in a manner determined by the Committee, generally over a four year period for employees and one year from grant for non-employee directors, and all options expire not more than 7 years from the date of the grant. At March 31, 2012, there were 2,182,028 shares subject to options, no shares of restricted stock outstanding and 160,763 shares subject to restricted stock units outstanding under this plan and 3,203,967 shares available for future grant.

The Company had a long-term incentive stock option plan and a non-qualified stock option plan, (the “2000 Long-term Incentive Plan”) which permitted the issuance of a maximum of 3,500,000 shares of our common stock pursuant to incentive and non-qualified stock options granted to key employees, officers and directors. The plan was terminated in connection with the adoption of the 2005 Incentive Compensation Plan. At March 31, 2012, there were 241,539 options outstanding under this plan and no further options will be granted under this plan.

The Company had a non-qualified stock option plan under which options were granted to non-employee directors and two previous plans under which options were granted to key employees. At March 31, 2012, there were no options outstanding related to these plans. No further options will be granted under these plans.

The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 700,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of our full-time employees are eligible to participate in the Purchase Plan.

The Purchase Plan provides for two “purchase periods” within each of our fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% nor more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.

Stock-based compensation expense of $9.3 million, $10.8 million, and $10.3 million was recognized under ASC Topic 718, Compensation — Stock Compensation, for the fiscal year ended March 31, 2012, April 2, 2011, and April 3, 2010, respectively. The related income tax benefit recognized was $2.7 million, $3.7 million, and $3.0 million for the fiscal year ended March 31, 2012, April 2, 2011, and April 3, 2010, respectively. We recognize stock-based compensation on a straight line basis.

ASC Topic 718 requires that cash flows relating to the benefits of tax deductions in excess of stock compensation cost recognized be reported as a financing cash flow, rather than as an operating cash flow. This excess tax benefit was $1.4 million, $3.1 million, and $0.4 million for the fiscal year ended March 31, 2012, April 2, 2011, and April 3, 2010, respectively.

A summary of stock option activity for the fiscal year ended March 31, 2012 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at April 2, 2011	2,446,843		$	48.94	4.09	$	43,149
Granted	464,837		62.29
Exercised	(369,092	)	42.00
Forfeited	(119,021	)	54.16
Outstanding at March 31, 2012	2,423,567		$	52.30	3.87	$	42,134
Exercisable at March 31, 2012	1,412,052		$	47.98	2.57	$	30,644
Vested or expected to vest at March 31, 2012	2,302,589		$	51.95	3.76	$	40,816

The total intrinsic value of options exercised was $8.5 million, $26.5 million, and $8.2 million during fiscal 2012, 2011, and 2010, respectively.

As of March 31, 2012, there was $11.1 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 2.6 years.

The fair value was estimated using the Black-Scholes option-pricing model based on the weighted average of the high and low stock prices at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of our common stock. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period. The assumptions utilized for option grants during the periods presented are as follows:



	March 31, 2012		April 2, 2011		April 3, 2010
Volatility	27.5	%	28.2	%	28.6	%
Expected life (years)	4.9		4.9		4.9
Risk-free interest rate	1.1	%	1.8	%	2.4	%
Dividend yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of options granted during 2012, 2011, and 2010 was approximately $16.31, $15.83, and $15.37, respectively.

We have applied, based on an analysis of our historical forfeitures, an annual forfeiture rate of 8% to all unvested stock options as of March 31, 2012 and April 2, 2011, which represents the portion that we expect will be forfeited each year over the vesting period.

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 31, 2012		April 2, 2011		April 3, 2010
Volatility	26.3	%	21.1	%	30.9	%
Expected life	6	mos.	6	mos.	6	mos.
Risk-free interest rate	0.1	%	0.2	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $14.19, $11.73, and $12.53 during fiscal 2012, 2011, and 2010, respectively.

Restricted Stock Awards

As of March 31, 2012, there was no unrecognized compensation cost related to non-vested restricted stock awards.

A summary of restricted stock awards activity for the fiscal year ended March 31, 2012 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Outstanding at April 2, 2011	2,500		$	48.09
Released	(2,500	)	$	48.09
Outstanding at March 31, 2012	—		$	—

Restricted Stock Units

As of March 31, 2012, there was $6.4 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 2.7 years.

A summary of restricted stock units activity for the fiscal year ended March 31, 2012 is as follows:



	Shares		Weighted Average Market Value at Grant Date
Nonvested at April 2, 2011	130,632		$	50.62
Awarded	90,228		$	59.81
Released	(45,064	)	$	61.45
Forfeited	(15,033	)	$	53.48
Nonvested at March 31, 2012	160,763		$	51.72

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

+ Details

EARNINGS PER SHARE ("EPS")

12 Months Ended

Mar. 31, 2012

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations as required by ASC Topic 260, Earnings Per Share. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares.



(In thousands, except per share amounts)	March 31, 2012		April 2, 2011		April 3, 2010
Basic EPS
Net income	$	66,886	$	79,980	$	58,370
Weighted average shares	25,364		25,077		25,451
Basic income per share	$	2.64	$	3.19	$	2.29
Diluted EPS
Net income	$	66,886	$	79,980	$	58,370
Basic weighted average shares	25,364		25,077		25,451
Net effect of common stock equivalents	431		519		612
Diluted weighted average shares	25,795		25,596		26,063
Diluted income per share	$	2.59	$	3.12	$	2.24

During 2012, 2011, and 2010, approximately 0.7 million, 1.2 million, and 0.9 million, respectively, potentially dilutive common shares were not included in the computation of diluted earnings per share because the inclusion of these potentially dilutive shares would be anti-dilutive.

COMPREHENSIVE INCOME

12 Months Ended

Mar. 31, 2012

Comprehensive Income [Abstract]

COMPREHENSIVE INCOME

Comprehensive income is the total of net income and all other non-owner changes in stockholders’ equity. Other non-owner changes are primarily foreign currency translation, the change in our net minimum pension liability, and the changes in fair value of the effective portion of our outstanding cash flow hedge contracts.

A summary of the components of other comprehensive income is as follows:



(In thousands)	Foreign Currency Translation			Unrealized Gain/(Loss) on Derivatives, Net of Tax			Impact of Defined Benefit Plans, Net of Tax			Accumulated Other Comprehensive Income
Balance as of April 3, 2010	$	5,271		$	1,454		$	(820	)	$	5,905
Changes during the year	6,380			(3,299		)	555			$	3,636
Balance as of April 2, 2011	$	11,651		$	(1,845	)	$	(265	)	$	9,541
Changes during the year	(2,813		)	6,370			(3,988		)	$	(431	)
Balance as of March 31, 2012	$	8,838		$	4,525		$	(4,253	)	$	9,110

- Definition

The entire disclosure for comprehensive income. Includes, but is not limited to, the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e709-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e640-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e716-108580

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e689-108580

+ Details

RETIREMENT PLANS

12 Months Ended

Mar. 31, 2012

Compensation and Retirement Disclosure [Abstract]

Compensation and Employee Benefit Plans [Text Block]

RETIREMENT PLANS

Defined Contribution Plans

We have a Savings Plus Plan that is a 401(k) plan that allows our U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the Plan based upon pre-established rates. Our matching contributions amounted to approximately $4.0 million in 2012, $3.3 million in 2011, and $3.0 million in 2010. Upon Board approval, additional discretionary contributions can also be made. No discretionary contributions were made for the Savings Plan in fiscal 2012, 2011, or 2010.

Some of our subsidiaries also have defined contribution plans, to which plan both the employee and the employer make contributions. The employer contributions to these plans totaled $0.8 million, $1.8 million, and $1.7 million in fiscal 2012, 2011, and 2010, respectively, of which $1.5 million, and $1.4 million in fiscal 2011, and 2010, respectively, were contributed for our employees in Switzerland.

During fiscal 2012, it was determined that the plan for our employees in Switzerland was a defined benefit plan rather than a defined contribution plan. For fiscal 2012, this plan has been accounted for as a defined benefit plan as described below.

Defined Benefit Plans

ASC Topic 715, Compensation — Retirement Benefits, requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit postretirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive income on its Statement of Stockholders’ Equity and Comprehensive Income.

Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates which are subject to change.

Some of the Company’s foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:



(In thousands)	March 31, 2012			April 2, 2011			April 3, 2010
Service cost	$	2,545		$	667		$	512
Interest cost on benefit obligation	601			283			242
Expected (return)/loss on plan assets	2			(467		)	(289		)
Actuarial (gain)/loss	(385		)	(48		)	223
Amortization of unrecognized prior service cost	(31		)	381			(68		)
Amortization of unrecognized transition obligation	221			30			27
Totals	$	2,953		$	846		$	647

The net periodic benefit costs shown above for fiscal 2012 include the associated costs for the Switzerland defined benefit plan. The net periodic benefit costs for fiscal 2011 and 2010 shown above have not been updated to reflect the Switzerland plan costs. These costs were approximately $1.5 million and $1.4 million for fiscal 2011 and 2010, respectively. During those periods, the Switzerland plan was accounted for as a defined contribution plan and Company contributions to the plan were expensed.

The activity under those defined benefit plans are as follows:



(In thousands)	March 31, 2012			April 2, 2011
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(8,628	)	$	(7,949	)
Switzerland Benefit Obligation, beginning of year	(14,079		)	n/a
Service cost	(2,545		)	(667		)
Interest cost	(601		)	(283		)
Benefits paid	1,952			843
Actuarial (loss)/gain	(1,244		)	102
Employee and plan participants contribution	(1,728		)
Plan Amendments	(193		)	—
Currency translation	(84		)	(674		)
Benefit obligation, end of year	$	(27,150	)	$	(8,628	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	4,449		$	3,833
Fair value of Switzerland plan assets, beginning of year	11,349			n/a
Company contributions	2,156			478
Benefits paid	(1,873		)	(783		)
Gain/(Loss) on plan assets	124			467
Employee and plan participants contributions	1,728			n/a
Currency translation	252			454
Fair value of Plan Assets, end of year	$	18,185		$	4,449
Funded Status	$	(8,965	)	$	(4,179	)
Unrecognized net actuarial loss/(gain)	4,513			341
Unrecognized initial obligation	141			(83		)
Unrecognized prior service cost	254			171
Net amount recognized	$	(4,057	)	$	(3,750	)

The fiscal 2012 amounts shown above include the Switzerland plan amounts. The fiscal 2011 amounts shown above have not been updated to reflect the Switzerland amounts. The benefit obligation for the Switzerland plan was approximately $14.1 million as of April 2, 2011. The fair value of the Switzerland plan assets as of April 2, 2011 was approximately $11.3 million.

One of the benefit plans is funded by benefit payments made by the Company. Accordingly that plan has no assets included in the information presented above. The total liability for this plan was $4.9 million and $4.1 million as of March 31, 2012 and April 2, 2011, respectively.

The accumulated benefit obligation for all plans was $22.5 million and $3.9 million for the fiscal year ended March 31, 2012 and April 2, 2011, respectively. The increase in the current fiscal year is due to the change in accounting for the Switzerland plan. The accumulated benefit obligation for fiscal 2011 has not been updated to reflect the Switzerland plan.

Amounts recognized as a component of other accrued liabilities on the balance sheet as of March 31, 2012 and April 2, 2011, under ASC Topic 715 totaled $9.0 million and $4.2 million, respectively.

The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance as of April 3, 2010	$	(820	)
Obligation at transition	574
Actuarial loss	(50		)
Prior service cost	31
Balance as of April 2, 2011	$	(265	)
Obligation at transition	30
Actuarial loss	(3,701		)
Prior service cost	(317		)
Balance as of March 31, 2012	$	(4,253	)

The weighted average rates used to determine the net periodic benefit costs were as follows:



	March 31, 2012		April 2, 2011		April 3, 2010
Discount rate	2.40	%	5.30	%	5.20	%
Rate of increased salary levels	1.50	%	2.60	%	2.00	%
Expected long-term rate of return on assets	2.10	%	1.60	%	1.60	%

Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets.

We have no other material obligation for post-retirement or post-employment benefits.

The Company’s investment policy for its pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements. For the Company's plans with assets, the majority of the investments are in fixed-income instruments such as bonds and time-deposits.

ASC Topic 820, Fair Value Measurements and Disclosures, provides guidance for reporting and measuring the plan assets of our defined benefit pension plan at fair value as of March 31, 2012. Using the same three- level valuation hierarchy for disclosure of fair value measurements as described in Note 7, all of the assets of the Company’s plan are classified within Level 1 of the fair value hierarchy because the plan assets are primarily local market and global fixed- income securities that are valued using prices quoted on the active market.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the company’s benefit obligation at March 31, 2012. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.

Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):



Expected Benefit Payments
Fiscal Year 2013	$	1,199
Fiscal Year 2014	$	1,428
Fiscal Year 2015	$	1,073
Fiscal Year 2016	$	1,429
Fiscal Year 2017	$	1,878
Fiscal Year 2018-2021	$	4,545

The Company contributions for fiscal 2013 are expected to be consistent with our recent historical experience.

SEGMENT INFORMATION

12 Months Ended

Mar. 31, 2012

Segment Reporting [Abstract]

SEGMENT INFORMATION

Segment Definition Criteria

We manage our business on the basis of one operating segment: the design, manufacture, and marketing of blood management solutions. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product categories.

Enterprise Wide Disclosures about Product and Services

We have four global product families: plasma, blood center, hospital, and software solutions.

Our products include equipment devices and the related disposables used with these devices. Disposables include the plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals (also known as source plasma). Blood center consists of disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients. Hospital consists of surgical disposables (principally the Cell Saver^® autologous blood recovery system targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries and the cardioPAT^® cardiovascular perioperative autotransfusion system designed to remain with the patient following surgery to recover blood and the patient’s red cells to prepare them for reinfusion), the OrthoPAT^® orthopedic perioperative autotransfusion system designed to operate both during and after surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG^® Thrombelastograph^® hemostasis analyzer used to help assess a surgical patient’s hemostasis (blood clotting ability) during and after surgery).

Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.

Revenues from External Customers:



(In thousands)	March 31, 2012		April 2, 2011		April 3, 2010
Disposable revenues
Plasma disposables	$	258,061	$	227,209	$	232,378
Blood center disposables
Platelet	167,946		156,251		151,026
Red cell	48,034		46,828		48,031
	215,980		203,079		199,057
Hospital disposables
Surgical	66,619		66,503		69,942
OrthoPAT	31,186		35,631		37,079
Diagnostics	23,087		19,414		16,770
	120,892		121,548		123,791
Disposables revenue	594,933		551,836		555,226
Software solutions	70,557		66,876		35,919
Equipment & other	62,354		57,982		54,285
Total revenues	$	727,844	$	676,694	$	645,430

Enterprise Wide Disclosures about Product and Services

Year ended (in thousands)



March 31, 2012	United States		Other North America		Total North America		Japan		Other Asia		Total Asia		Total Europe		Total Consolidated
Sales	$	352,160	$	512	$	352,672	$	124,381	$	67,223	$	191,604	$	183,568	$	727,844
Total Assets	$	634,171	$	15,365	$	649,536	$	50,509	$	27,353	$	77,862	$	183,737	$	911,135
Long-Lived Assets	$	305,370	$	12,796	$	318,166	$	13,128	$	3,961	$	17,089	$	38,009	$	373,264



April 2, 2011	United States		Other North America		Total North America		Japan		Other Asia		Total Asia		Total Europe		Total Consolidated
Sales	$	316,447	$	908	$	317,355	$	110,263	$	61,594	$	171,857	$	187,482	$	676,694
Total Assets	$	582,733	$	15,903	$	598,636	$	47,156	$	18,164	$	65,320	$	169,308	$	833,264
Long-Lived Assets	$	305,305	$	12,715	$	318,020	$	12,391	$	4,181	$	16,572	$	38,092	$	372,684



April 3, 2010	United States		Other North America		Total North America		Japan		Other Asia		Total Asia		Total Europe		Total Consolidated
Sales	$	301,774	$	2,191	$	303,965	$	109,573	$	51,324	$	160,897	$	180,568	$	645,430
Total Assets	$	487,955	$	22,941	$	510,896	$	42,438	$	20,928	$	63,366	$	190,043	$	764,305
Long-Lived Assets	$	313,241	$	16,800	$	330,041	$	11,230	$	3,805	$	15,035	$	19,285	$	364,361

The Long-Lived Assets reported above include Goodwill, Other Intangibles and Net Property, Plant and Equipment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

+ Details

RESTRUCTURING

12 Months Ended

Mar. 31, 2012

Restructuring and Related Activities [Abstract]

RESTRUCTURING

During fiscal 2012, the Company's restructuring activities primarily consist of reorganization within our research and development, manufacturing and software operations. Employee-related costs primarily consist of employee severance and benefits. Facility-related costs primarily consist of charges associated with closing facilities, related lease obligations, and other related costs.

For fiscal 2012, the Company incurred $5.9 million of restructuring charges. Restructuring expenses have been primarily included as a component of selling, general and administrative expense in the accompanying statements of income.

On April 1, 2010, our Board of Directors approved transformation and restructuring plans, which include the integration of Global Med Technologies, Inc. During fiscal 2011, in addition to the costs in the below table and as part of our approved transformation and restructuring plans, we incurred the following expenses:


•	Stock compensation expense of $1.7 million resulting from the acceleration of unvested stock options in accordance to terms of an employment contract for an employee. This expense is included as part of our restructuring charges and reflected in our consolidated statement of income as selling, general and administrative expense for the fiscal year ended April 2, 2011.


•	$2.1 million of integration costs related to the Global Med acquisition.

During fiscal 2010, in connection with the transformation plan, we had an asset write down of $15.7 million related to the abandonment of our next generation platelet apheresis platform and our blood center donation management software, as well as $8.6 million in transformation costs related to the separation of employees and reflected in our consolidated statement of income as selling, general and administrative expense.

The following summarizes the restructuring activity for the fiscal year ended March 31, 2012, April 2, 2011, and April 3, 2010, respectively:



(In thousands)	Balance at April 2, 2011		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at March 31, 2012
Employee-related costs	$	2,782	$	4,112	$	(5,433	)	$	—	$	1,461
Facility related costs	889		1,746		(2,102		)	—		533
	$	3,671	$	5,858	$	(7,535	)	$	—	$	1,994



(In thousands)	Balance at April 3, 2010		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at April 2, 2011
Employee-related costs	$	9,761	$	3,595	$	(10,574	)	$	—	$	2,782
Facility related costs	—		89		—			—		889
	$	9,761	$	3,684	$	(10,574	)	$	—	$	3,671



(In thousands)	Balance at March 28, 2009		Cost Incurred		Payments			Asset Write down			Restructuring Accrual Balance at April 3, 2010
Employee-related costs	$	2,729	$	8,598	$	(1,566	)	$	—		$	9,761
Facility related costs	42		—		(42		)	—			—
Other exit & termination costs	78		15,686		(78		)	(15,686		)	—
	$	2,849	$	24,284	$	(1,686	)	$	(15,686	)	$	9,761

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	12 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Mar. 31, 2012
Capitalization of Software and Development Costs [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS The cost of software that is developed or obtained for internal use is accounted for pursuant to ASC Topic 350, Intangibles — Goodwill and Other. Pursuant to ASC Topic 350, the Company capitalizes costs incurred during the application development stage of software developed for internal use, and expenses costs incurred during the preliminary project and the post-implementation operation stages of development. The Company capitalized $3.6 million and $2.8 million in costs incurred for acquisition of the software license and related software development costs for new internal software that was in the application development stage during the fiscal year ended March 31, 2012 and April 2, 2011, respectively. The capitalized costs are included as a component of property, plant and equipment in the consolidated financial statements. For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. The Company capitalized $6.1 million, $6.9 million and $4.7 million in software development costs for ongoing initiatives during the fiscal year ended March 31, 2012, April 2, 2011 and April 3, 2010, respectively. At March 31, 2012 and April 2, 2011, we have a total of $19.5 million and $13.4 million, respectively, of software costs capitalized, of which $15.4 million and $13.4 million, respectively, related to in process software development initiatives. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. In connection with these development activities, we capitalized interest of $0.2 million and $0.1 million in fiscal 2012 and 2011, respectively. We will begin to amortize the remaining costs when the products are released for sale. In the first quarter of fiscal 2012, $4.1 million of costs capitalized related to one in-process project were placed into service. During fiscal 2010, in connection with the change in our technology strategy and restructuring of our Research and Development organization, the Company decided to abandon our software development project for our next generation blood center apheresis platform. At April 2, 2011, we had an asset impairment of $12.2 million in total capitalized software development costs of this project in accordance with ASC Topic 985-20, as the net realizable value of the capitalized software was insufficient to recover the asset amount capitalized. Additionally during fiscal 2010, in connection with our acquisition of Global Med, we had an asset impairment of $3.5 million in capitalized costs of other software development initiatives in accordance with ASC Topic 985-20, as the net realizable value of the capitalized software was insufficient to recover the asset amount capitalized.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Audit and Accounting Guide (AAG)
-Number AAG-FGC
-Chapter 3
-Paragraph 56, 57
-IssueDate 2006-05-01
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 68
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

+ Details

SUMMARY OF QUARTERLY DATA (UNAUDITED)

12 Months Ended

Mar. 31, 2012

Quarterly Financial Data [Abstract]

SUMMARY OF QUARTERLY DATA (UNAUDITED)



	First Quarter		Second Quarter		Third Quarter		Fourth Quarter
Fiscal year ended March 31, 2012:
Net revenues	$	170,569	$	179,445	$	191,160	$	186,670
Gross profit	$	88,748	$	89,949	$	95,931	$	94,612
Operating income	$	23,908	$	18,566	$	25,324	$	20,960
Net income	$	16,947	$	13,880	$	18,254	$	17,805
Share data:
Net Income:
Basic	$	0.66	$	0.55	$	0.73	$	0.71
Diluted	$	0.65	$	0.54	$	0.72	$	0.69
Fiscal year ended April 2, 2011:
Net revenues	$	163,039	$	166,833	$	176,789	$	170,033
Gross profit	$	86,463	$	87,755	$	93,490	$	87,501
Operating income	$	24,189	$	28,905	$	28,559	$	28,895
Net income	$	17,918	$	21,338	$	19,734	$	20,989
Share data:
Net Income:
Basic	$	0.71	$	0.86	$	0.79	$	0.82
Diluted	$	0.70	$	0.85	$	0.77	$	0.81

Operating income and net income declined in the second quarter of fiscal 2012 as increases in operating expenses more than offset gross profit associated with revenue growth due to higher costs of quality, relatively higher sales of our lower-margin products and expenses associated with European customer claims arising from a quality matter with HS Core.

Gross profit declined during the fourth quarter of fiscal 2011 due to a decline in sales volume and increased inventory reserves. Operating income remained flat during the same period due to a reduction in cash bonus incentive compensation as the Company’s financial results were lower than the financial targets established at the beginning of the year.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

SUBSEQUENT EVENTS (UNAUDITED)	12 Months Ended
SUBSEQUENT EVENTS (UNAUDITED)	Mar. 31, 2012
Subsequent Events [Abstract]
SUBSEQUENT EVENTS (UNAUDITED)	SUBSEQUENT EVENTS (UNAUDITED) On April 28, 2012, Haemonetics Corporation entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Pall Corporation (“Pall”), pursuant to which Haemonetics agreed to acquire from Pall (i) substantially all of the assets relating to its blood collection, filtration, processing, storage and re-infusion product lines, and (ii) all of the outstanding equity interest in Pall Mexico Manufacturing, S. de R.L. de C.V, a subsidiary of Pall based in Mexico (collectively, the “Product Lines” and such transaction, the “Transaction”). At the closing of the Transaction, subject to adjustments (upward or downward) to reflect (i) the audited adjusted operating income of the Product Lines before depreciation, amortization and non-cash restructuring charges for Pall's fiscal year ended July 31, 2011, and (ii) the amount of actual Product Line inventory being acquired, Haemonetics will pay to Pall $551 million in cash consideration, subject to a holdback of $15 million, which will be payable upon the replication and delivery of certain manufacturing assets of Pall's filter media business to Haemonetics by 2016. Until that time, Pall will manage these assets under a supply agreement with Haemonetics. The Purchase Agreement includes customary representations, warranties and covenants of Pall and Haemonetics, as well as indemnification provisions for breaches or inaccuracies in either party's representations and warranties or covenants. Under the Purchase Agreement, Pall has agreed to operate the Product Lines in the ordinary course of business consistent with past practice until the closing of the Transaction. In addition, Pall will be restricted from discussing or otherwise agreeing to a competing transaction with respect to the Product Lines, and Haemonetics will be restricted from discussing or otherwise agreeing to acquire any assets, entities, businesses or product lines that compete with the Product Lines, or from acquiring any assets or entities if such acquisition could reasonably be expected to increase the risk of not obtaining necessary governmental approvals or to materially delay the completion of the Transaction. The Transaction is expected to close in the second quarter of Haemonetics' fiscal 2013, subject to the conditions precedent set forth in the Purchase Agreement, receipt of necessary regulatory and third-party approvals and labor-related notifications, as well as a period of confirmatory due diligence by Haemonetics. If in the course of conducting such confirmatory due diligence, Haemonetics discovers matters or issues that would adversely affect the Product Lines above certain thresholds, Haemonetics will have the right to terminate the Purchase Agreement. The Purchase Agreement also includes other customary termination provisions for both Haemonetics and Pall and provides that if, after all closing conditions are satisfied, one party refuses to consummate the Transaction, the other party will be entitled to a termination fee in an amount equal to $17 million, which will be the sole and exclusive remedy in such circumstances. Haemonetics intends to finance the purchase price primarily with $475 million of new borrowings under term loans. JPMorgan Chase Bank N.A. and Citibank N.A. (together, the “Lenders”) have committed to provide Haemonetics a term loan facility in an initial aggregate principal amount of $475 million, and J.P. Morgan Securities LLC and Citibank, N.A. have agreed to use commercially reasonable efforts to syndicate a revolving credit facility in a maximum aggregate principal amount of $50 million, both of which facilities will be unsecured, on the terms and subject to the conditions set forth in a debt commitment letter (the “Debt Commitment Letter”). The obligation of the Lenders to provide debt financing under the Debt Commitment Letter is subject to a number of conditions, including, among other things, (i) no material adverse condition or material adverse change in or affecting the business, property, financial condition or operations of Haemonetics and its subsidiaries (both before and, on a pro forma basis, after giving effect to the Transaction), taken as a whole, (ii) the execution and delivery of definitive financing documentation and other customary closing certificates, documents and instruments, (iii) the Transaction being consummated pursuant to the Purchase Agreement, with no provision of the Purchase Agreement having been amended or waived in a manner materially adverse to the Lenders, and (iv) Haemonetics having demonstrated that it will be in pro forma compliance with all financial covenants. The final termination date for the Debt Commitment Letter is August 1, 2012. Also, on April 28, 2012, Haemonetics announced that it had entered into a definitive agreement to acquire the business assets of Hemerus Medical, LLC, a Minnesota-based company that develops innovative technologies for the collection of whole blood, and processing and storage of blood components. Hemerus has completed Phase 3 clinical trials and has submitted a New Drug Application to the FDA for its unique, patented SOLX® whole blood collection system. This system's features include a collection set and a storage solution that is believed to considerably extend the quality and effective life of red blood cells. Hemerus expects FDA approval in calendar year 2012. The storage solution is the result of research partially funded by the US Army, and invented by Dr. John Hess of the University of Maryland, and the late Dr. Tibor Greenwalt of the University of Cincinnati. Hemerus holds the exclusive worldwide license to the intellectual property and furthered this research through the development of a whole blood collection set and clinical trials. Under terms of the agreement, Haemonetics will pay up to $27 million in several stages, each of which is contingent upon successful regulatory approvals of SOLX. Additionally, Haemonetics has agreed to pay a royalty on future sales of SOLX based products. The acquisition is expected to close during the second quarter of fiscal 2013.

VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Mar. 31, 2012

Valuation and Qualifying Accounts [Abstract]

VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II

HAEMONETICS CORPORATION

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Period		Charged to Costs and Expenses			Write-Offs (Net of Recoveries)			Balance at End of Period
For Year Ended March 31, 2012
Allowance for Doubtful Accounts	$	1,799	$	(39	)	$	(280	)	$	1,480
For Year Ended April 2, 2011
Allowance for Doubtful Accounts	$	2,554	$	343		$	(1,098	)	$	1,799
For Year Ended April 3, 2010
Allowance for Doubtful Accounts	$	2,312	$	363		$	(121	)	$	2,554

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)	12 Months Ended
	Mar. 31, 2012
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Fiscal Year	Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2012 and 2011 each includes 52 weeks with each quarter having 13 weeks. Fiscal year 2010 includes 53 weeks with each of the first three quarters having 13 weeks and the fourth quarter having 14 weeks.
Principles of Consolidation	The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions.
Reclassifications	Certain reclassifications have been made to prior years’ amounts to conform to the current year’s presentation.
Revenue Recognition	Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition, and ASC Topic 985-605, Software. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software, we establish fair value of undelivered elements based upon vendor specific objective evidence.
Product Revenues	Product sales consist of the sale of our equipment devices and the related disposables used with these devices. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. All shipments to distributors are at contract prices and payment is not contingent upon resale of the product.
Collection of Taxes from Customers	We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority.
Software Solutions and Services Revenues	Our software solutions business provides support to our plasma and blood collection customers and hospitals. Through our Haemonetics Software Solutions unit, we provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities. Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. With the acquisition of Global Med, a significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees. We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.
Translation of Foreign Currencies	All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from inter-company transactions, are included in other income, net on the consolidated statements of income.
Cash and Cash Equivalents	Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 31, 2012, our cash and cash equivalents consisted of investments in United States Government Agency and Institutional Money Market Funds.
Allowance for Doubtful Accounts	We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables. We establish allowances for balances not yet due and past due accounts based on past experience.
Concentration of Credit Risk and Significant Customers	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society, amounted to $99.5 million, $95.9 million, and $92.6 million for 2012, 2011, and 2010, respectively. Accounts receivable balances attributable to this customer accounted for 15.3%, 13.7%, and 12.6% of our consolidated accounts receivable at fiscal year ended 2012, 2011, and 2010. Sales to another global healthcare customer, "Customer B", amounted to $79.9 million in fiscal 2012. Accounts receivable balances attributable to this customer accounted for 6.6% of our consolidated accounts receivable at fiscal year ended 2012. While the accounts receivable related to the Japanese Red Cross Society and Customer B may be significant, we do not believe the credit loss risk to be significant given the consistent payment history by these customers. Certain other markets and industries can expose us to concentrations of credit risk. For example, in our commercial plasma business, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these commercial plasma customers can be somewhat significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods. Deteriorating credit and economic conditions in parts of Western Europe, particularly in Italy where our net accounts receivable was $21.0 million as of March 31, 2012 and $20.4 million as of April 2, 2011, may increase the average length of time it takes us to collect our accounts receivable in certain regions within these countries.
Goodwill and Other Intangible Assets	Intangible assets acquired in a business combination, including licensed technology, are recorded under the purchase method of accounting at their estimated fair values at the date of acquisition. Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. We amortize our other intangible assets over their useful lives using the estimated economic benefit method, as applicable. Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles — Goodwill and Other. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. The test is based on a discounted cash flow analysis for each reporting unit. The test showed no evidence of impairment to our goodwill for either fiscal 2012, 2011 or 2010 and demonstrated that the fair value of each reporting unit significantly exceeded the reporting unit’s carrying value in each period. We review our intangible assets, subject to amortization, and their related useful lives periodically to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. Our review includes examination of whether certain conditions exist, including: a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the market place including changes in the prices paid for our products or changes in the size of the market for our products. An impairment loss results if the carrying value of the asset exceeds the estimated fair value of the asset. Fair value is determined using different methodologies depending upon the nature of the underlying asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life.
Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed	ASC Topic 985-20, Software, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed. We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded. At the end of fiscal 2010, based on a review of ongoing development plans for our next generation platelet apheresis products (Portico), we abandoned and wrote off $12.2 million associated with previously capitalized software development costs. Additionally, in connection with the acquisition of Global Med we elected to no longer market the Symphony blood center donation management system in favor of Global Med’s El Dorado application. As a result, we wrote off the carrying value of the Symphony intangible asset totaling approximately $3.5 million.
Other Liabilities	Other liabilities represent items payable within the next twelve months.
Research and Development Expenses	All research and development costs are expensed as incurred.
Advertising Costs	All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statement of income.
Accounting for Shipping and Handling Costs	Shipping and handling costs are included in costs of goods sold with the exception of $10.9 million for fiscal 2012, $9.7 million for fiscal 2011, and $11.2 million for fiscal 2010 that are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.
Income Taxes	The income tax provision is calculated for all jurisdictions in which we operate. This process involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. Deferred tax assets are periodically evaluated to determine their recoverability and a valuation allowance is established with a corresponding additional income tax provision recorded in our consolidated statements of income if their recovery is not considered more likely than not. The provision for income taxes could also be materially impacted if actual taxes due differ from our earlier estimates. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Uncertain tax positions are unrecognized tax benefits for which reserves have been established. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities’ full knowledge of the position and all relevant facts. We file income tax returns in all jurisdictions in which we operate. We establish reserves to provide for additional income taxes that may be due in future years as these previously filed tax returns are audited. These reserves have been established based on management’s assessment as to the potential exposure attributable to permanent differences and interest applicable to both permanent and temporary differences. All tax reserves are analyzed periodically and adjustments are made as events occur that warrant modification.
Foreign Currency	We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with ASC Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship. The gains or losses on the forward exchange contracts designated as hedges are recorded in net revenues, cost of goods sold, and operating expenses in our consolidated statements of income when the underlying hedged transaction affects earnings. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. The Company recorded foreign currency losses of $0.4 million, $1.4 million, and $2.2 million in fiscal 2012, 2011 and 2010, respectively. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.
Stock-Based Compensation	We use the Black-Scholes option-pricing model to calculate the grant-date fair value of our stock options. The following assumptions, which involve the use of judgment by management, are used in the computation of the grant-date fair value of our stock options: Expected Volatility — We have principally used our historical volatility as a basis to estimate expected volatility in our valuation of stock options. Expected Term — We estimate the expected term of our options using historical exercise and forfeiture data. We believe that this historical data is currently the best estimate of the expected term of our new option grants. Additionally, after determining the fair value of our stock options, we use judgment in establishing an estimated forfeiture rate, to determine the amount of stock based compensation to record each period: Estimated Forfeiture Rate — We have applied, based on an analysis of our historical forfeitures, an annual forfeiture rate which represents the portion that we expect will be forfeited each year over the vesting period. We reevaluate this analysis periodically and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.
Valuation of Acquisitions	We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The use of alternative valuation assumptions, including estimated cash flows and discount rates, and alternative estimated useful life assumptions could result in different purchase price allocations and intangible asset amortization expense in current and future periods. In certain acquisitions, we have earn-out arrangements or contingent consideration to provide potential future payments to the seller for achieving certain agreed-upon financial targets. We record the contingent consideration at its fair value at the acquisition date. Generally, we have entered into arrangements with contingent consideration that require payments in cash. As such, each quarter, we revalue the contingent consideration obligations associated with certain acquisitions to their then fair value and record the change in the fair value as contingent consideration income or expense. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in assumed discount periods and rates, changes in the assumed timing and amount of revenue and expense estimates, and changes in assumed probability adjustments with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration income or expense we record in any given period.

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)

12 Months Ended

Mar. 31, 2012

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Schedule of Property, Plant and Equipment Estimated Useful Lives



Asset Classification		Estimated Useful Lives
Building		30 Years
Building improvements		5-20 Years
Leasehold improvements		5 Years
Plant equipment and machinery		3-10 Years
Office equipment and information technology		3-9 Years
Haemonetics equipment		2-6 Years

Depreciation expense was $38.6 million, $37.0 million, and $35.5 million for fiscal 2012, 2011, and 2010, respectively.


•	Purchase and consumption of a certain level of disposable products


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Schedule of Other Accrued Liabilities

The significant items included in the fiscal year end balances were:



(In thousands)	March 31, 2012		April 2, 2011
VAT Liabilities	$	6,875	$	11,867
Forward Contracts	1,185		4,174
Deferred Revenue	24,132		21,740
HS Core Liability	3,654		—
All Other	20,989		8,475
Total	$	56,835	$	46,256

ACQUISITIONS (Tables)

12 Months Ended

Mar. 31, 2012

Global Med Technologies, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Final Purchase Price Allocation

The following chart summarizes the final purchase price allocation:



	(In thousands)
Goodwill	$	39,554
Intangible assets subject to amortization	39,920
Trade accounts receivable	6,848
Other assets	7,639
Deferred taxes	(10,928		)
Notes payable	(7,701		)
Deferred revenue	(7,180		)
Other liabilities	(7,725		)
Total	$	60,427

PRODUCT WARRANTIES (Tables)

12 Months Ended

Mar. 31, 2012

Product Warranties [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	March 31, 2012			April 2, 2011
Warranty accrual as of the beginning of the period	$	1,273		$	903
Warranty provision	2,430			1,823
Warranty spending	(2,907		)	(1,453		)
Warranty accrual as of the end of the period	$	796		$	1,273

INVENTORIES (Tables)

12 Months Ended

Mar. 31, 2012

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.



(In thousands)	March 31, 2012		April 2, 2011
Raw materials	$	41,219	$	26,404
Work-in-process	4,640		4,352
Finished goods	71,304		53,631
	$	117,163	$	84,387

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

12 Months Ended

Mar. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill for fiscal 2012 and 2011 are as follows:



	(In thousands)
Carrying amount as of April 3, 2010	$	109,988
SEBRA (a)	163
Altivation Software Inc.	228
ACCS (b)	2,662
Effect of change in foreign currency exchange rates	2,326
Carrying amount as of April 2, 2011	$	115,367
Effect of change in foreign currency exchange rates	(309		)
Carrying amount as of March 31, 2012	$	115,058

_______________________________________


(a)	See Note 3, Acquisitions, for a full description of the acquisition of the SEBRA^® assets, which occurred on September 4, 2009.


(b)	See Note 3, Acquisitions, for a full description of the acquisition of Applied Critical Care Services, Inc. (“ACCS”), which occurred on December 28, 2010.

Schedule of Amoritized Intangibles

Amortized Intangibles



	Gross Carrying Amount		Accumulated Amortization		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In years)
As of March 31, 2012
Patents	$	13,463	$	7,843	11
Capitalized software	20,597		1,394		6
Other technology	42,693		20,120		11
Customer contracts and related relationships	69,361		23,639		12
Trade names	5,408		1,977		10
Total intangibles	$	151,522	$	54,973	11



	Gross Carrying Amount		Accumulated Amortization		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In years)
As of April 2, 2011
Patents	$	12,704	$	6,827	11
Capitalized software	14,506		656		6
Other technology	43,244		17,391		11
Customer contracts and related relationships	69,908		17,740		12
Trade names	5,254		1,213		10
Total intangibles	$	145,616	$	43,827	11

- Definition

Tabular disclosure of goodwill by reportable segment and in total. Disclosure details may include, but are not limited to, the carrying amount of goodwill, goodwill acquired during the year, goodwill impairment losses recognized, goodwill written-off due to the sale of a business unit, goodwill not yet allocated, and any other changes to goodwill.

+ References + Details

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Mar. 31, 2012

Derivatives and Fair Value Measurements [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



Derivative Instruments (In thousands)	Amount of Gain/(Loss) Recognized in OCI (Effective Portion)		Amount of Loss Reclassified from OCI into Earnings (Effective Portion)			Location in Statement of Operations	Amount of Gain/(Loss) Excluded from Effectiveness Testing (*)			Location in Statement of Operations
Designated foreign currency hedge contracts	$	3,140	$	(3,230	)	Net revenues, COGS, and SG&A	$	67		Other income (expense), net
Non-designated foreign currency contracts							$	(1,666	)	Other income (expense), net
	$	3,140	$	(3,230	)		$	(1,599	)

_______________________________________



(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets



(In thousands)	Location in Balance Sheet	Balance as of March 31, 2012		Balance as of April 2, 2011
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	6,186	$	2,563
		$	6,186	$	2,563
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,185	$	4,174
		$	1,185	$	4,174

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 31, 2012:



(In thousands)	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Money market funds	$	194,574	$	—	$	—	$	194,574
Forward currency exchange contracts	—		6,186		—		6,186
	$	194,574	$	6,186	$	—	$	200,760
Liabilities
Forward currency exchange contracts	$	—	$	1,185	$	—	$	1,185
Other liabilities — contingent consideration	—		—		—		—
	$	—	$	1,185	$	—	$	1,185

- Definition

Tabular disclosure of the location and amount of gains and losses reported in the statement of financial performance, or when applicable, the statement of financial position. For example, (a) gains and losses recognized in the income statement on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges and (b) gains and losses initially recognized in other comprehensive income on derivative instruments designated and qualifying as cash flow hedges.

+ References + Details

INCOME TAXES (Tables)

12 Months Ended

Mar. 31, 2012

Income Tax Disclosure [Abstract]

Schedule Domestic and Foreign Income Before Provision for Income Tax

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	March 31, 2012		April 2, 2011		April 3, 2010
Domestic	$	40,666	$	58,040	$	42,260
Foreign	$	48,832	$	52,041	$	39,011
Total	$	89,498	$	110,081	$	81,271

Schedule of Income Tax Provision Components

The income tax provision contains the following components:



(In thousands)	March 31, 2012			April 2, 2011		April 3, 2010
Current
Federal	$	8,505		$	14,982	$	10,088
State	2,275			2,111		887
Foreign	5,954			7,226		9,334
Total current	$	16,734		$	24,319	$	20,309
Deferred
Federal	7,522			4,931		4,103
State	(597		)	438		259
Foreign	(1,047		)	413		(1,770		)
Total deferred	$	5,878		$	5,782	$	2,592
Total	$	22,612		$	30,101	$	22,901

Schedule of Net Deferred Tax Asset

Tax affected, significant temporary differences comprising the net deferred tax assets/(liabilities) are as follows:



(In thousands)	March 31, 2012			April 2, 2011
Depreciation	$	(17,208	)	$	(9,447	)
Amortization	(19,249		)	(20,597		)
Inventory	4,224			2,244
Hedging	(589		)	1,120
Accruals and reserves	6,352			5,950
Net operating loss carry-forward	3,354			7,241
Stock Based Compensation	8,649			7,725
Tax credit carry-forward, net	2,328			1,583
Gross Deferred Taxes	(12,139		)	(4,181		)
Less valuation allowance	$	(1,569	)	$	(3,630	)
Net deferred tax liabilities	$	(13,708	)	$	(7,811	)

Schedule of Effective Income Tax Rate Reconciliation

The income tax provision from operations differs from tax provision computed at the 35% U.S. federal statutory income tax rate due to the following:



(In thousands)	March 31, 2012					April 2, 2011					April 3, 2010

Tax at federal statutory rate	$	31,324		35.0	%	$	38,528		35.0	%	$	28,444		35.0	%
Domestic Manufacturing Deduction	(700		)	(0.8	)%	(1,120		)	(1.0	)%	(883		)	(1.1	)%
Difference between U.S. and foreign tax	(8,539		)	(9.5	)%	(8,610		)	(7.9	)%	(4,392		)	(5.4	)%
State income taxes net of federal benefit	1,136			1.3	%	1,741			1.6	%	764			0.9	%
Repatriation of Earnings	—			—	%	(506		)	(0.5	)%	(1,574		)	(1.9	)%
Other, net	(609		)	(0.7	)%	68			0.1	%	542			0.7	%
Income tax provision	$	22,612		25.3	%	$	30,101		27.3	%	$	22,901		28.2	%

Summary of Gross Unrecognized Tax Benefits

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ending April 2, 2011 and March 31, 2012:



(In thousands)	March 31, 2012			April 2, 2011
Beginning Balance	$	4,669		$	4,620
Additions based upon positions related to the current year	1,124			20
Additions for tax positions of prior years	1,216			1,641
Reductions of tax positions	(124		)	(1,042		)
Settlements with taxing authorities	—			—
Closure of statute of limitations	—			(570		)
Ending Balance	$	6,885		$	4,669

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References + Details

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

12 Months Ended

Mar. 31, 2012

Notes Payable and Long-Term Debt [Abstract]

Schedule of Notes Payable and Long-Term Debt

Notes payable and long-term debt consisted of the following:



(In thousands)	March 31, 2012		April 2, 2011
Real estate mortgage	$	3,771	$	4,590
Short-term notes payable	—		289
	$	3,771	$	4,879
Less-Current portion	$	894	$	913
	$	2,877	$	3,966

Schedule of Notes Payable and Long-Term Debt Maturities

As of March 31, 2012, notes payable and long-term debt matures as follows (in thousands):



Fiscal Year Ending
2013	$	894
2014	971
2015	1,056
2016	850
2017 and thereafter	—
	$	3,771

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Mar. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

Schedule of Approximate Future Basic Rental Commitments under Operating Leases

Approximate future basic rental commitments under operating leases as of March 31, 2012 are as follows (in thousands):



Fiscal Year Ending
2013	$	6,169
2014	4,093
2015	2,718
2016	2,320
2017	1,852
Thereafter	2,456
	$	19,608

CAPITAL STOCK (Tables)

12 Months Ended

Mar. 31, 2012

Capital Stock [Abstract]

Schedule of Summary of Stock Option Activity

A summary of stock option activity for the fiscal year ended March 31, 2012 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at April 2, 2011	2,446,843		$	48.94	4.09	$	43,149
Granted	464,837		62.29
Exercised	(369,092	)	42.00
Forfeited	(119,021	)	54.16
Outstanding at March 31, 2012	2,423,567		$	52.30	3.87	$	42,134
Exercisable at March 31, 2012	1,412,052		$	47.98	2.57	$	30,644
Vested or expected to vest at March 31, 2012	2,302,589		$	51.95	3.76	$	40,816

Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for option grants during the periods presented are as follows:



	March 31, 2012		April 2, 2011		April 3, 2010
Volatility	27.5	%	28.2	%	28.6	%
Expected life (years)	4.9		4.9		4.9
Risk-free interest rate	1.1	%	1.8	%	2.4	%
Dividend yield	0.0	%	0.0	%	0.0	%

Schedule of Assumptions Used to Estimate Fair Value of Shares Purchased Under ESPP

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 31, 2012		April 2, 2011		April 3, 2010
Volatility	26.3	%	21.1	%	30.9	%
Expected life	6	mos.	6	mos.	6	mos.
Risk-free interest rate	0.1	%	0.2	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average rates used to determine the net periodic benefit costs were as follows:



	March 31, 2012		April 2, 2011		April 3, 2010
Discount rate	2.40	%	5.30	%	5.20	%
Rate of increased salary levels	1.50	%	2.60	%	2.00	%
Expected long-term rate of return on assets	2.10	%	1.60	%	1.60	%

Schedule of Summary of Restricted Stock Awards Activity

A summary of restricted stock awards activity for the fiscal year ended March 31, 2012 is as follows:



	Shares		Weighted Average Grant Date Fair Value
Outstanding at April 2, 2011	2,500		$	48.09
Released	(2,500	)	$	48.09
Outstanding at March 31, 2012	—		$	—

Schedule of Summary of Restricted Stock Units Activity

A summary of restricted stock units activity for the fiscal year ended March 31, 2012 is as follows:



	Shares		Weighted Average Market Value at Grant Date
Nonvested at April 2, 2011	130,632		$	50.62
Awarded	90,228		$	59.81
Released	(45,064	)	$	61.45
Forfeited	(15,033	)	$	53.48
Nonvested at March 31, 2012	160,763		$	51.72

EARNINGS PER SHARE ("EPS") (Tables)

12 Months Ended

Mar. 31, 2012

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation



(In thousands, except per share amounts)	March 31, 2012		April 2, 2011		April 3, 2010
Basic EPS
Net income	$	66,886	$	79,980	$	58,370
Weighted average shares	25,364		25,077		25,451
Basic income per share	$	2.64	$	3.19	$	2.29
Diluted EPS
Net income	$	66,886	$	79,980	$	58,370
Basic weighted average shares	25,364		25,077		25,451
Net effect of common stock equivalents	431		519		612
Diluted weighted average shares	25,795		25,596		26,063
Diluted income per share	$	2.59	$	3.12	$	2.24

COMPREHENSIVE INCOME (Tables)

12 Months Ended

Mar. 31, 2012

Comprehensive Income [Abstract]

Schedule of Comprehensive Income (Loss)

A summary of the components of other comprehensive income is as follows:



(In thousands)	Foreign Currency Translation			Unrealized Gain/(Loss) on Derivatives, Net of Tax			Impact of Defined Benefit Plans, Net of Tax			Accumulated Other Comprehensive Income
Balance as of April 3, 2010	$	5,271		$	1,454		$	(820	)	$	5,905
Changes during the year	6,380			(3,299		)	555			$	3,636
Balance as of April 2, 2011	$	11,651		$	(1,845	)	$	(265	)	$	9,541
Changes during the year	(2,813		)	6,370			(3,988		)	$	(431	)
Balance as of March 31, 2012	$	8,838		$	4,525		$	(4,253	)	$	9,110

RETIREMENT PLANS (Tables)

12 Months Ended

Mar. 31, 2012

Compensation and Retirement Disclosure [Abstract]

Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans



(In thousands)	March 31, 2012			April 2, 2011			April 3, 2010
Service cost	$	2,545		$	667		$	512
Interest cost on benefit obligation	601			283			242
Expected (return)/loss on plan assets	2			(467		)	(289		)
Actuarial (gain)/loss	(385		)	(48		)	223
Amortization of unrecognized prior service cost	(31		)	381			(68		)
Amortization of unrecognized transition obligation	221			30			27
Totals	$	2,953		$	846		$	647

Schedule of Activity Under Defined Benefit Plans

The activity under those defined benefit plans are as follows:



(In thousands)	March 31, 2012			April 2, 2011
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(8,628	)	$	(7,949	)
Switzerland Benefit Obligation, beginning of year	(14,079		)	n/a
Service cost	(2,545		)	(667		)
Interest cost	(601		)	(283		)
Benefits paid	1,952			843
Actuarial (loss)/gain	(1,244		)	102
Employee and plan participants contribution	(1,728		)
Plan Amendments	(193		)	—
Currency translation	(84		)	(674		)
Benefit obligation, end of year	$	(27,150	)	$	(8,628	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	4,449		$	3,833
Fair value of Switzerland plan assets, beginning of year	11,349			n/a
Company contributions	2,156			478
Benefits paid	(1,873		)	(783		)
Gain/(Loss) on plan assets	124			467
Employee and plan participants contributions	1,728			n/a
Currency translation	252			454
Fair value of Plan Assets, end of year	$	18,185		$	4,449
Funded Status	$	(8,965	)	$	(4,179	)
Unrecognized net actuarial loss/(gain)	4,513			341
Unrecognized initial obligation	141			(83		)
Unrecognized prior service cost	254			171
Net amount recognized	$	(4,057	)	$	(3,750	)

Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax

The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance as of April 3, 2010	$	(820	)
Obligation at transition	574
Actuarial loss	(50		)
Prior service cost	31
Balance as of April 2, 2011	$	(265	)
Obligation at transition	30
Actuarial loss	(3,701		)
Prior service cost	(317		)
Balance as of March 31, 2012	$	(4,253	)

Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 31, 2012		April 2, 2011		April 3, 2010
Volatility	26.3	%	21.1	%	30.9	%
Expected life	6	mos.	6	mos.	6	mos.
Risk-free interest rate	0.1	%	0.2	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average rates used to determine the net periodic benefit costs were as follows:



	March 31, 2012		April 2, 2011		April 3, 2010
Discount rate	2.40	%	5.30	%	5.20	%
Rate of increased salary levels	1.50	%	2.60	%	2.00	%
Expected long-term rate of return on assets	2.10	%	1.60	%	1.60	%

Schedule of Estimated Future Benefit Payments

Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):



Expected Benefit Payments
Fiscal Year 2013	$	1,199
Fiscal Year 2014	$	1,428
Fiscal Year 2015	$	1,073
Fiscal Year 2016	$	1,429
Fiscal Year 2017	$	1,878
Fiscal Year 2018-2021	$	4,545

SEGMENT INFORMATION (Tables)

12 Months Ended

Mar. 31, 2012

Segment Reporting [Abstract]

Schedule of Revenues from External Customers

Revenues from External Customers:



(In thousands)	March 31, 2012		April 2, 2011		April 3, 2010
Disposable revenues
Plasma disposables	$	258,061	$	227,209	$	232,378
Blood center disposables
Platelet	167,946		156,251		151,026
Red cell	48,034		46,828		48,031
	215,980		203,079		199,057
Hospital disposables
Surgical	66,619		66,503		69,942
OrthoPAT	31,186		35,631		37,079
Diagnostics	23,087		19,414		16,770
	120,892		121,548		123,791
Disposables revenue	594,933		551,836		555,226
Software solutions	70,557		66,876		35,919
Equipment & other	62,354		57,982		54,285
Total revenues	$	727,844	$	676,694	$	645,430

Enterprise Wide Disclosures about Product and Services

Year ended (in thousands)



March 31, 2012	United States		Other North America		Total North America		Japan		Other Asia		Total Asia		Total Europe		Total Consolidated
Sales	$	352,160	$	512	$	352,672	$	124,381	$	67,223	$	191,604	$	183,568	$	727,844
Total Assets	$	634,171	$	15,365	$	649,536	$	50,509	$	27,353	$	77,862	$	183,737	$	911,135
Long-Lived Assets	$	305,370	$	12,796	$	318,166	$	13,128	$	3,961	$	17,089	$	38,009	$	373,264



April 2, 2011	United States		Other North America		Total North America		Japan		Other Asia		Total Asia		Total Europe		Total Consolidated
Sales	$	316,447	$	908	$	317,355	$	110,263	$	61,594	$	171,857	$	187,482	$	676,694
Total Assets	$	582,733	$	15,903	$	598,636	$	47,156	$	18,164	$	65,320	$	169,308	$	833,264
Long-Lived Assets	$	305,305	$	12,715	$	318,020	$	12,391	$	4,181	$	16,572	$	38,092	$	372,684



April 3, 2010	United States		Other North America		Total North America		Japan		Other Asia		Total Asia		Total Europe		Total Consolidated
Sales	$	301,774	$	2,191	$	303,965	$	109,573	$	51,324	$	160,897	$	180,568	$	645,430
Total Assets	$	487,955	$	22,941	$	510,896	$	42,438	$	20,928	$	63,366	$	190,043	$	764,305
Long-Lived Assets	$	313,241	$	16,800	$	330,041	$	11,230	$	3,805	$	15,035	$	19,285	$	364,361

RESTRUCTURING (Tables)

12 Months Ended

Mar. 31, 2012

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The following summarizes the restructuring activity for the fiscal year ended March 31, 2012, April 2, 2011, and April 3, 2010, respectively:



(In thousands)	Balance at April 2, 2011		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at March 31, 2012
Employee-related costs	$	2,782	$	4,112	$	(5,433	)	$	—	$	1,461
Facility related costs	889		1,746		(2,102		)	—		533
	$	3,671	$	5,858	$	(7,535	)	$	—	$	1,994



(In thousands)	Balance at April 3, 2010		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at April 2, 2011
Employee-related costs	$	9,761	$	3,595	$	(10,574	)	$	—	$	2,782
Facility related costs	—		89		—			—		889
	$	9,761	$	3,684	$	(10,574	)	$	—	$	3,671



(In thousands)	Balance at March 28, 2009		Cost Incurred		Payments			Asset Write down			Restructuring Accrual Balance at April 3, 2010
Employee-related costs	$	2,729	$	8,598	$	(1,566	)	$	—		$	9,761
Facility related costs	42		—		(42		)	—			—
Other exit & termination costs	78		15,686		(78		)	(15,686		)	—
	$	2,849	$	24,284	$	(1,686	)	$	(15,686	)	$	9,761

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Tables)

12 Months Ended

Mar. 31, 2012

Quarterly Financial Data [Abstract]

Schedule of Quarterly Data



	First Quarter		Second Quarter		Third Quarter		Fourth Quarter
Fiscal year ended March 31, 2012:
Net revenues	$	170,569	$	179,445	$	191,160	$	186,670
Gross profit	$	88,748	$	89,949	$	95,931	$	94,612
Operating income	$	23,908	$	18,566	$	25,324	$	20,960
Net income	$	16,947	$	13,880	$	18,254	$	17,805
Share data:
Net Income:
Basic	$	0.66	$	0.55	$	0.73	$	0.71
Diluted	$	0.65	$	0.54	$	0.72	$	0.69
Fiscal year ended April 2, 2011:
Net revenues	$	163,039	$	166,833	$	176,789	$	170,033
Gross profit	$	86,463	$	87,755	$	93,490	$	87,501
Operating income	$	24,189	$	28,905	$	28,559	$	28,895
Net income	$	17,918	$	21,338	$	19,734	$	20,989
Share data:
Net Income:
Basic	$	0.71	$	0.86	$	0.79	$	0.82
Diluted	$	0.70	$	0.85	$	0.77	$	0.81

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Narrative) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2012 USD ($) yr Customers	Apr. 02, 2011 USD ($) Customers	Apr. 03, 2010 USD ($) Customers
Summary of Significant Accounting Pronouncements [Line Items]
Number of weeks in each fiscal year	P52W	P52W	P53W
Number of weeks in each quarter	P13W	P13W
Cash and cash equivalents maximum maturity period	3 months
Depreciation expense	$ 38,600	$ 37,000	$ 35,500
Capitalized software impairment		12,200
Intangible asset impairment		3,500
VAT Liabilities	6,875	11,867
Forward Contracts	1,185	4,174
Deferred Revenue	24,132	21,740
HS Core Liability	3,654	0
All Other	20,989	8,475
Total	56,835	46,256
Advertising expense	4,500	2,800	1,600
Shipping and handling costs	10,900	9,700	11,200
Foreign currency loss	$ 400	$ 1,400	$ 2,200
First Three Quarters [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Number of weeks in each quarter			P13W
Fourth Quarter [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Number of weeks in each quarter			P14W
Building [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life (in years) \| yr	30
Building Improvements [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life, minimum (in years) \| yr	5
Property, plant and equipment, useful life, maximum (in years) \| yr	20
Leasehold Improvements [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life (in years) \| yr	5
Plant Equipment and Machinery [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life, minimum (in years) \| yr	3
Property, plant and equipment, useful life, maximum (in years) \| yr	10
Office Equipment and Information Technology [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life, minimum (in years) \| yr	3
Property, plant and equipment, useful life, maximum (in years) \| yr	9
Haemonetics Equipment [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life, minimum (in years) \| yr	2
Property, plant and equipment, useful life, maximum (in years) \| yr	6
Japanese Red Cross Society [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Concentration risk (as a percent)	15.30%	13.70%	12.60%
Japanese Red Cross Society [Member] \| Sales [Member] \| Customer Concentration Risk [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Concentration risk, number of customers \| Customers	1	1	1
Credit risk, accounts receivable	$ 99,500	$ 95,900	$ 92,600
Customer B [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Concentration risk (as a percent)	6.60%
Customer B [Member] \| Sales [Member] \| Customer Concentration Risk [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Credit risk, accounts receivable	$ 79,900
Italy \| Sales [Member] \| Deteriorating Credit and Economic Conditions [Member]
Summary of Significant Accounting Pronouncements [Line Items]
Credit risk, accounts receivable	$ 21,000	$ 20,400

ACQUISITIONS (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
ACQUISITIONS (Details) - USD ($) $ in Thousands	Sep. 30, 2011	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010	Dec. 28, 2010	Mar. 31, 2010	Sep. 04, 2009	Apr. 16, 2009
Business Acquisition [Line Items]
Notes payable		$ 0	$ 0	$ (5,132)
Contingent consideration, reduction of contingent liability		(1,580)	(1,894)	(2,345)
Reversal of interest expense on contingent consideration		574	416	(588)
Applied Critical Care Services, Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, cost of acquired entity, purchase price					$ 6,400
Business acquisition, purchase price allocation, other liabilities					800
Goodwill					2,700
Global Med Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, cost of acquired entity, purchase price						$ 60,400
Goodwill		39,554
Intangible assets subject to amortization		39,920
Trade accounts receivable		6,848
Other assets		7,639
Deferred taxes		(10,928)
Notes payable		(7,701)
Deferred revenue		(7,180)
Other liabilities		(7,725)
Total		60,427
SEBRA of Engineering and Research Associates, Inc [Member]
Business Acquisition [Line Items]
Business acquisition, cost of acquired entity, purchase price							$ 12,800
Goodwill							3,700
Trade accounts receivable							1,000
Business acquisition, purchase price allocation, inventory							1,100
Neoteric [Member]
Business Acquisition [Line Items]
Business acquisition, cost of acquired entity, purchase price								$ 6,600
Goodwill								8,200
Intangible assets subject to amortization								5,000
Deferred taxes								$ (1,600)
Contingent consideration, reduction of contingent liability		(1,600)
Reversal of interest expense on contingent consideration		$ 600	$ 600	$ (400)
Contingent consideration paid for settlement	$ 700
Customer Relationships [Member] \| Applied Critical Care Services, Inc. [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization					$ 4,500
Customer Relationships [Member] \| SEBRA of Engineering and Research Associates, Inc [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization							4,600
Core Technology [Member] \| SEBRA of Engineering and Research Associates, Inc [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization							2,000
Trade Names [Member] \| SEBRA of Engineering and Research Associates, Inc [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization							$ 400

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011
Product Warranties [Abstract]
General warranty period on parts and labor (in years)	1 year	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$ 1,273	$ 903
Warranty provision	2,430	1,823
Warranty spending	(2,907)	(1,453)
Warranty accrual as of the end of the period	$ 796	$ 1,273

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011
Inventory Disclosure [Abstract]
Raw materials	$ 41,219	$ 26,404
Work-in-process	4,640	4,352
Finished goods	71,304	53,631
Inventories, net	$ 117,163	$ 84,387

GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2012

Apr. 02, 2011

Goodwill [Roll Forward]

Goodwill, carrying amount

$ 115,367

$ 109,988

Effect of change in foreign currency exchange rates

(309)

2,326

Goodwill, carrying amount

$ 115,058

115,367

SEBRA of Engineering and Research Associates, Inc [Member]

Goodwill [Roll Forward]

Goodwill acquired during period

^[1]

163

Altivation Software [Member]

Goodwill [Roll Forward]

Goodwill acquired during period

228

Applied Critical Care Services, Inc. [Member]

Goodwill [Roll Forward]

Goodwill acquired during period

^[2]

$ 2,662

[1]	See Note 3, Acquisitions, for a full description of the acquisition of the SEBRA® assets, which occurred on September 4, 2009.
[2]	See Note 3, Acquisitions, for a full description of the acquisition of Applied Critical Care Services, Inc. (“ACCS”), which occurred on December 28, 2010.

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

GOODWILL AND OTHER INTANGIBLE ASSETS Intangible Assets (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2012 USD ($) yr	Apr. 02, 2011 USD ($) yr	Apr. 03, 2010 USD ($)
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 151,522	$ 145,616
Accumulated Amortization	$ 54,973	$ 43,827
Weighted Average Useful Life (In years) \| yr	11	11
Amortization of Intangible Assets	$ 11,400	$ 11,100	$ 7,700
Future amortization expense, year one	11,000
Future amortization expense, year two	10,700
Future amortization expense, year three	10,100
Future amortization expense, year four	9,700
Future amortization expense, year five	9,400
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	13,463	12,704
Accumulated Amortization	$ 7,843	$ 6,827
Weighted Average Useful Life (In years) \| yr	11	11
Capitalized Software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 20,597	$ 14,506
Accumulated Amortization	$ 1,394	$ 656
Weighted Average Useful Life (In years) \| yr	6	6
Other Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 42,693	$ 43,244
Accumulated Amortization	$ 20,120	$ 17,391
Weighted Average Useful Life (In years) \| yr	11	11
Customer Contracts and Related Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 69,361	$ 69,908
Accumulated Amortization	$ 23,639	$ 17,740
Weighted Average Useful Life (In years) \| yr	12	12
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 5,408	$ 5,254
Accumulated Amortization	$ 1,977	$ 1,213
Weighted Average Useful Life (In years) \| yr	10	10
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (In years) \| yr	5
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (In years) \| yr	20

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2011	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding		$ 162,100	$ 154,800
Non-designated foreign currency hedge contracts outstanding		45,500	45,900
Contingent consideration income		1,580	1,894	$ 2,345
Reversal of interest expense on contingent consideration		574	416	(588)
Fair value of real estate mortgage obligation		$ 1,185
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US		51.60%
Maturity period for foreign currency contracts (in years)		1 year
Amount of gains (losses) reclassified to earnings within the next twelve months		$ (3,230)
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Amount of gains (losses) reclassified to earnings within the next twelve months		3,100	(4,100)
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract
Derivative [Line Items]
Recognized net losses in earnings on cash flow hedges		3,200	800
Mortgage Loans on Real Estate
Derivative [Line Items]
Fair value of real estate mortgage obligation		3,100	4,100
Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] \| Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract
Derivative [Line Items]
Amount of gains (losses) reclassified to earnings within the next twelve months		(3,230)
Neoteric [Member]
Derivative [Line Items]
Contingent consideration income		1,600
Reversal of interest expense on contingent consideration		$ 600	600	$ (400)
Business acquisition, contingent consideration outstanding			$ 2,300
Contingent consideration payment recorded in selling, general and administrative	$ 700

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - Foreign Exchange Contract - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2012

Apr. 02, 2011

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in OCI (Effective Portion)

$ 3,140

Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)

(3,230)

Amount Excluded from Effectiveness Testing

^[1]

(1,599)

Designated as Hedging Instrument

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)

3,100

$ (4,100)

Designated as Hedging Instrument | Cash Flow Hedging | Net revenues, COGS, and SG&A

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in OCI (Effective Portion)

3,140

Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)

(3,230)

Designated as Hedging Instrument | Cash Flow Hedging | Other Income (Expense), Net [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Amount Excluded from Effectiveness Testing

^[1]

Not Designated as Hedging Instrument | Other Income (Expense), Net [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Amount Excluded from Effectiveness Testing

^[1]

$ (1,666)

[1]	(*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011
Derivative Assets:
Derivative Assets	$ 6,186	$ 2,563
Derivative Liabilities:
Derivative Liabilities	1,185	4,174
Cash Flow Hedging \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	6,186	2,563
Cash Flow Hedging \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 1,185	$ 4,174

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis) (Details) $ in Thousands	Mar. 31, 2012 USD ($)
Assets
Money market funds	$ 194,574
Foreign currency hedge contracts	6,186
Assets, Fair Value Disclosure, Total	200,760
Liabilities
Foreign currency hedge contracts	1,185
Other liabilities - contingent consideration	0
Liabilities, Fair Value Disclosure, Total	1,185
Quoted Market Prices for Identical Assets (Level 1) [Member]
Assets
Money market funds	194,574
Foreign currency hedge contracts	0
Assets, Fair Value Disclosure, Total	194,574
Liabilities
Foreign currency hedge contracts	0
Other liabilities - contingent consideration	0
Liabilities, Fair Value Disclosure, Total	0
Significant Other Observable Inputs (Level 2) [Member]
Assets
Money market funds	0
Foreign currency hedge contracts	6,186
Assets, Fair Value Disclosure, Total	6,186
Liabilities
Foreign currency hedge contracts	1,185
Other liabilities - contingent consideration	0
Liabilities, Fair Value Disclosure, Total	1,185
Significant Unobervable Inputs (Level 3) [Member]
Assets
Money market funds	0
Foreign currency hedge contracts	0
Assets, Fair Value Disclosure, Total	0
Liabilities
Foreign currency hedge contracts	0
Other liabilities - contingent consideration	0
Liabilities, Fair Value Disclosure, Total	$ 0

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Income Taxes [Line Items]
Foregin source income	$ 48,832	$ 52,041	$ 39,011
Acquisition related valuation allowance	1,569	$ 3,630
Foreign subsidiary undistributed earnings permanently reinvested outside the US	2,300
Gross federal and state tax credits available	$ 167,000
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%
Unrecognized tax benefits	$ 6,885	$ 4,669	$ 4,620
Unrecognized tax benefits that will impact effective tax rate	6,600	4,300
Unrecognized tax benefitsreduced by expiration of statute of limitations and settlements with taxing authoritites	2,100
Unrecognized tax benefits offset by establishment of reserves	200
Unrecognized tax positions possible change in the next twelve months	800
Accrued interest and penalties	1,000	700
Internal Revenue Service (IRS) [Member]
Income Taxes [Line Items]
Foreign income tax provision	1,600	10,800	8,100
Foregin source income	6,200	$ 31,000	$ 23,200
United States Acquisitions [Member]
Income Taxes [Line Items]
Acquisition related operating loss carryforwards	4,700
Canada Acquisitions [Member]
Income Taxes [Line Items]
Acquisition related operating loss carryforwards	1,200
Acquisition Related Research and Development [Member]
Income Taxes [Line Items]
Acquisition related valuation allowance	400
Acquisition Related Net Operating Losses [Member]
Income Taxes [Line Items]
Acquisition related valuation allowance	$ 1,200

NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details) - Mortgages [Member] - USD ($) $ in Millions	1 Months Ended
	Dec. 31, 2000	Mar. 31, 2012	Apr. 02, 2011	Dec. 02, 2000
Debt Instrument [Line Items]
Face amount of mortgage agreement				$ 10.0
Mortgage required principal and interest payments per month	$ 0.1
Term of mortgage agreement	180 months
Mortgage agreement interest rate per annum	8.41%
Carrying value of mortgage		$ 3.8	$ 4.6

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Income Tax Disclosure [Abstract]
Domestic	$ 40,666	$ 58,040	$ 42,260
Foreign	48,832	52,041	39,011
Income before provision for income taxes	$ 89,498	$ 110,081	$ 81,271

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011
Debt Instrument [Line Items]
Long-term Debt	$ 3,771	$ 4,879
Less-Current portion	894	913
Long-term debt, net of current maturities	2,877	3,966
Mortgages [Member]
Debt Instrument [Line Items]
Real estate mortgage	3,771	4,590
Short Term Notes Payable [Member]
Debt Instrument [Line Items]
Short-term notes payable	$ 0	$ 289

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Current
Federal	$ 8,505	$ 14,982	$ 10,088
State	2,275	2,111	887
Foreign	5,954	7,226	9,334
Total current	16,734	24,319	20,309
Deferred
Federal	7,522	4,931	4,103
State	(597)	438	259
Foreign	(1,047)	413	(1,770)
Total deferred	5,878	5,782	2,592
Total	$ 22,612	$ 30,101	$ 22,901

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011
Notes Payable and Long-Term Debt [Abstract]
2013	$ 894
2014	971
2015	1,056
2016	850
2017 and thereafter	0
Long-term Debt	$ 3,771	$ 4,879

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) - USD ($) $ in Thousands	Mar. 31, 2012	Apr. 02, 2011
Income Tax Disclosure [Abstract]
Depreciation	$ (17,208)	$ (9,447)
Amortization	(19,249)	(20,597)
Inventory	4,224	2,244
Hedging	(589)	1,120
Accruals and reserves	6,352	5,950
Net operating loss carryforward	3,354	7,241
Stock based compensation	8,649	7,725
Tax credit carryforward, net	2,328	1,583
Gross Deferred Taxes	(12,139)	(4,181)
Less valuation allowance	(1,569)	(3,630)
Net deferred tax asset	$ (13,708)	$ (7,811)

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ 31,324	$ 38,528	$ 28,444
Tax at federal statutory rate, percent	35.00%	35.00%	35.00%
Domestic Manufacturing Deduction and Extraterritorial Income Exclusion	$ (700)	$ (1,120)	$ (883)
Domestic Manufacturing Deduction and Extraterritorial Income Exclusion, Percent	(0.80%)	(1.00%)	(1.10%)
Difference between U.S. and foreign tax	$ (8,539)	$ (8,610)	$ (4,392)
Difference between U.S. and foreign tax, percent	(9.50%)	(7.90%)	(5.40%)
State income taxes net of federal benefit	$ 1,136	$ 1,741	$ 764
State income taxes net of federal benefit, percent	1.30%	1.60%	0.90%
In Process Research and Dividend repatriation	$ 0	$ (506)	$ (1,574)
In Process Research and Dividend repatriation, percent	0.00%	(0.50%)	(1.90%)
Other, net	$ (609)	$ 68	$ 542
Other, net, percent	(0.70%)	0.10%	0.70%
Total	$ 22,612	$ 30,101	$ 22,901
Income tax provision, percent	25.30%	27.30%	28.20%

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning Balance	$ 4,669	$ 4,620
Additions based upon positions related to the current year	1,124	20
Additions for tax positions of prior years	1,216	1,641
Reductions of tax positions	(124)	(1,042)
Settlements with taxing authorities	0	0
Closure of statute of limitations	0	(570)
Ending Balance	$ 6,885	$ 4,669

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) $ in Millions	1 Months Ended			12 Months Ended
	Sep. 30, 2011 USD ($)	Jan. 31, 2009 EUR (€)	Apr. 30, 2008 Employees	Mar. 31, 2012 USD ($)	Apr. 02, 2011 USD ($)	Apr. 03, 2010 USD ($)
Loss Contingencies [Line Items]
Rent expense				$ 6.1	$ 6.6	$ 5.9
Damages from Product Defects [Member] \| High Separation Core Bowl [Member]
Loss Contingencies [Line Items]
Estimate of liability				10.0
Accrued loss contingency liability				3.7
Estimated recovery of accrued liability from insurance				3.2
Recorded expense, net of insurance recovery within selling, general, and administrative expense				$ 3.1
Neoteric [Member]
Loss Contingencies [Line Items]
Contingent consideration paid for settlement	$ 0.7
Fenwal [Member]
Loss Contingencies [Line Items]
Term of Patent Infringement Lawsuits				5 years
Haemonetics Italia, Srl. [Member]
Loss Contingencies [Line Items]
Number of employees found guilty \| Employees			2
Damages awarded \| €		€ 147,500

COMMITMENTS AND CONTINGENCIES (Schedule of Approximate Future Basic Rental Commitments under Operating Leases) (Details) $ in Thousands	Mar. 31, 2012 USD ($)
Loss Contingencies [Line Items]
2013	$ 6,169
2014	4,093
2015	2,718
2016	2,320
2017	1,852
Thereafter	2,456
Operating Leases, Future Minimum Payments Due	$ 19,608

CAPITAL STOCK (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2012 USD ($) yr Members PreviousOptionPlans PurchasePeriods $ / shares shares	Apr. 02, 2011 USD ($) $ / shares shares	Apr. 03, 2010 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	2,423,567	2,446,843
Stock-based compensation expense recognized \| $	$ 9,300	$ 10,800	$ 10,300
Income tax benefit recognized related to stock-based compensation \| $	2,700	3,700	3,000
Excess tax benefit on exercise of stock options \| $	1,433	3,124	421
Total intrinsic value of options exercised \| $	$ 8,500	$ 26,500	$ 8,200
Weighted average grant date fair value of options granted (in dollars per share) \| $ / shares	$ 16.31	$ 15.83	$ 15.37
Annual unvested stock option forfeiture rate (as a percent)	8.00%
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share) \| $ / shares	$ 14.19	$ 11.73	$ 12.53
2005 Incentive Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of members on board of directors (in board members) \| Members	3
Maximum number of shares available for award (in shares)	7,512,460
Maximum number of shares available for grant (in shares)	3,203,967
Number of options counted against maximum number of award shares for every share option issued (in shares)	1
Number of equity instruments other than options counted against maximum number of award shares for every share granted (in shares)	3.26
Period in which awards become exercisable for employees (in years)	4 years
Period after grant that awards become exercisable for non-employee directors (in years)	1 year
Maximum number of years from grant date that options expire (in years)	7 years
Annual unvested stock option forfeiture rate (as a percent)		8.00%
2000 Long-term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	3,500,000
Maximum number of shares available for grant (in shares)	0
Options outstanding (in shares)	241,539
Previous Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)	0
Number of previous options plans (in previous option plans) \| PreviousOptionPlans	2
Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	700,000
Number of purchase periods (in purchase periods) \| PurchasePeriods	2
Percentage of purchase price for shares of common stock at fair market value (as a percent)	85.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)	500,000
Options outstanding (in shares)	2,182,028
Total unrecognized compensation cost related to non vested awards \| $	$ 11,100
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years) \| yr	2.6
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	0	2,500
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	160,763	130,632
Total unrecognized compensation cost related to non vested awards \| $	$ 6,400
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years) \| yr	2.7
Minimum [Member] \| Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	2.00%
Maximum [Member] \| Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	15.00%

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2012 USD ($) yr $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (shares), Beginning Balance \| shares	2,446,843
Weighted Average Exercise Price per Share, Beginning Balance \| $ / shares	$ 48.94
Weighted Average Remaining Life (years), Beginning Balance \| yr	4.09
Aggregate Intrinsic Value, Beginning Balance \| $	$ 43,149
Options Outstanding, (shares), Granted \| shares	464,837
Weighted Average Exercise Price per Share, Granted \| $ / shares	$ 62.29
Options Outstanding, (shares), Exercised \| shares	(369,092)
Weighted Average Exercise Price per Share, Exercised \| $ / shares	$ 42.00
Options Outstanding, (shares), Forfeited \| shares	(119,021)
Weighted Average Exercise Price per Share, Forfeited \| $ / shares	$ 54.16
Options Outstanding, (shares), Ending Balance \| shares	2,423,567
Weighted Average Exercise Price per Share, Ending Balance \| $ / shares	$ 52.30
Weighted Average Remaining Life (years), Ending Balance \| yr	3.87
Aggregate Intrinsic Value, Ending Balance \| $	$ 42,134
Options Outstanding, (shares), Exercisable and End of Period \| shares	1,412,052
Weighted Average Exercise Price per Share, Exercisable at End of Period \| $ / shares	$ 47.98
Weighted Average Remaining Life (years), Exercisable at End of Period \| yr	2.57
Aggregate Intrinsic Value, Exercisable at End of Period \| $	$ 30,644
Options Outstanding, (shares), Vested and Expected to Vest at End of Period \| shares	2,302,589
Weighted Average Exercise Price per Share, Vested or Expected to Vest at End of Period \| $ / shares	$ 51.95
Weighted Average Remaining Life (years), Vested or Expected to Vest at End of Period \| yr	3.76
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period \| $	$ 40,816

CAPITAL STOCK (Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants) (Details) - Stock Options [Member] - yr	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	27.50%	28.20%	28.60%
Expected life (in years)	4.9	4.9	4.9
Risk-free interest rate	1.10%	1.80%	2.40%
Dividend yield	0.00%	0.00%	0.00%

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value of Shares Purchased Under ESPP) (Details) - Employee Stock Purchase Plan [Member] - mo	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	26.30%	21.10%	30.90%
Expected life (in months)	6	6	6
Risk-free interest rate	0.10%	0.20%	0.20%
Dividend yield	0.00%	0.00%	0.00%

CAPITAL STOCK (Schedule of Summary of Restricted Stock Awards Activity) (Details) - Restricted Stock [Member]	12 Months Ended
	Mar. 31, 2012 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance \| shares	2,500
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 48.09
Shares, Released \| shares	(2,500)
Weighted Average Grant Date Fair Value, Released \| $ / shares	$ 48.09
Shares, Ending Balance \| shares	0
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	$ 0.00

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References + Details

CAPITAL STOCK (Schedule of Summary of Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Mar. 31, 2012 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance \| shares	130,632
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 50.62
Shares, Awarded \| shares	90,228
Weighted Average Market Value at Grant Date, Awarded \| $ / shares	$ 59.81
Shares, Released \| shares	(45,064)
Weighted Average Market Value at Grant Date, Released \| $ / shares	$ 61.45
Shares, Forfeited \| shares	(15,033)
Weighted Average Market Value at Grant Date, Forfeited \| $ / shares	$ 53.48
Shares, Ending Balance \| shares	160,763
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	$ 51.72

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Apr. 02, 2011	Jan. 01, 2011	Oct. 02, 2010	Jul. 03, 2010	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Basic EPS
Net income	$ 17,805	$ 18,254	$ 13,880	$ 16,947	$ 20,989	$ 19,734	$ 21,338	$ 17,918	$ 66,886	$ 79,980	$ 58,370
Basic weighted average shares (in shares)									25,364	25,077	25,451
Basic income per share (in dollars per share)	$ 0.71	$ 0.73	$ 0.55	$ 0.66	$ 0.82	$ 0.79	$ 0.86	$ 0.71	$ 2.64	$ 3.19	$ 2.29
Diluted EPS
Net income	$ 17,805	$ 18,254	$ 13,880	$ 16,947	$ 20,989	$ 19,734	$ 21,338	$ 17,918	$ 66,886	$ 79,980	$ 58,370
Basic weighted average shares (in shares)									25,364	25,077	25,451
Net effect of common stock equivalents (in shares)									431	519	612
Diluted weighted average shares (in shares)									25,795	25,596	26,063
Diluted income per share (in dollars per share)	$ 0.69	$ 0.72	$ 0.54	$ 0.65	$ 0.81	$ 0.77	$ 0.85	$ 0.70	$ 2.59	$ 3.12	$ 2.24
Stock options excluded from computation of weighted average shares outstanding									700	1,200	900

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 20

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 7
-Paragraph 18

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COMPREHENSIVE INCOME (Schedule of Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Increase (Decrease) in Comprehensive Income
Foreign Currency Translation, Balance	$ 11,651	$ 5,271
Foreign Currency Translation	(2,813)	6,380	$ 2,599
Foreign Currency Translation, Balance	8,838	11,651	5,271
Unrealized Gain/(Loss) on Derivatives, Net of Tax, Balance	(1,845)	1,454
Unrealized Gain/(Loss) on Derivatives, Net of Tax	6,370	(3,299)
Unrealized Gain/(Loss) on Derivatives, Net of Tax, Balance	4,525	(1,845)	1,454
Impact of Defined Benefit Plans, Net of Tax, Balance	(265)	(820)
Impact of Defined Benefit Plans, Net of Tax	(3,988)	555
Impact of Defined Benefit Plans, Net of Tax, Balance	(4,253)	(265)	(820)
Total accumulated comprehensive income	9,541	5,905
Total comprehensive income	(431)	3,636
Total accumulated comprehensive income	$ 9,110	$ 9,541	$ 5,905

- Definition

The total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

+ Details

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 18, 19, 22, 23, 24, 25, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 31
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

+ Details

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

+ Details

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 8, 9, 10, 11, 12, 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A5
-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6508144

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 19, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 13, 20, 31
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The after-tax amount of the change in the additional pension liability not yet recognized pursuant to FAS 87 par 37 and 38 as a net periodic pension cost. If the additional pension liability required to be recognized exceeds the unrecognized prior service costs, then the excess (which is the net loss not yet recognized as net periodic pension cost) is to be recorded as a reduction of other comprehensive income, before adjusting for tax effects. If in a subsequent measurement, the amount of minimum liability is eliminated or adjusted, this adjustment is offset against other comprehensive income in Accumulated Comprehensive Income. This line also includes changes in an entity's share of an equity investee's Increase or Decrease in additional pension liability not yet recognized as a net periodic pension cost. Eliminated upon adoption of FAS 158.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph c(5)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 19, 20-25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RETIREMENT PLANS (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	$ 2,156	$ 478
Net periodic benefit costs	2,953	846	$ 647
Benefit obligation	27,150	8,628	7,949
Fair value of plan assets	18,185	4,449	3,833
Accumulated benefit obligation	22,500	3,900
Amounts recognized as a component of other accrued liabilities on balance sheet	9,000	4,200
Savings Plus Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	4,000	3,300	3,000
Defined Contribution Plans [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	800	1,800	1,700
Benefit Plan Funded Through Assets of the Company [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Benefit obligation	4,900	4,100
Switzerland [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net periodic benefit costs		1,500	1,400
Benefit obligation	14,100	14,079
Fair value of plan assets	$ 11,300	11,349
Switzerland [Member] \| Defined Contribution Plans [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions		$ 1,500	$ 1,400

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 2,545	$ 667	$ 512
Interest cost on benefit obligation	601	283	242
Expected (return)/loss on plan assets	2	(467)	(289)
Actuarial (gain)/loss	(385)	(48)	223
Amortization of unrecognized prior service cost	(31)	381	(68)
Amortization of unrecognized transition obligation	221	30	27
Totals	$ 2,953	$ 846	$ 647

- Definition

An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets.

+ References

+ Details

- Definition

The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.

+ References + Details

- Definition

The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period. The portion of the expected postretirement benefit obligation attributed to employee service during the period. The service cost component is a portion of the benefit obligation and is unaffected by the funded status of the plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a, h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Service Cost (Component of Net Periodic Pension Cost)
-URI http://asc.fasb.org/extlink&oid=6525008

+ Details

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$ (8,628)	$ (7,949)
Service cost	(2,545)	(667)	$ (512)
Interest cost	(601)	(283)	(242)
Benefits paid	1,952	843
Actuarial (loss)/gain	(1,244)	102
Employee and plan participants contributions	(1,728)
Plan Amendments	(193)	0
Currency translation	(84)	(674)
Benefit obligation, end of year	(27,150)	(8,628)	(7,949)
Change in Plan Assets:
Fair value of plan assets, beginning of year	4,449	3,833
Company contributions	2,156	478
Benefits paid	(1,873)	(783)
Gain/(Loss) on plan assets	124	467
Employee and plan participants contributions	1,728
Currency translation	252	454
Fair value of Plan Assets, end of year	18,185	4,449	$ 3,833
Funded Status	(8,965)	(4,179)
Unrecognized net actuarial loss/(gain)	4,513	341
Unrecognized initial obligation	141	(83)
Unrecognized prior service cost	254	171
Net amount recognized	(4,057)	(3,750)
Switzerland [Member]
Change in Benefit Obligation:
Benefit Obligation, beginning of year	(14,079)
Benefit obligation, end of year	(14,100)	(14,079)
Change in Plan Assets:
Fair value of plan assets, beginning of year	11,349
Fair value of Plan Assets, end of year	$ 11,300	$ 11,349

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (265)	$ (820)
Obligation at transition	30	574
Actuarial loss	(3,701)	(50)
Prior service cost	(317)	31
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (4,253)	$ (265)

The cost (credit) resulting from a plan amendment that occurred during the period, after tax. The cost has not been recognized in net periodic benefit cost. A plan amendment includes provisions that grant increased benefits based on service rendered in prior periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 4
-Subparagraph c, d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 19, 24
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The accumulated change in the value of either the projected benefit obligation or the plan assets resulting from experience different from that assumed or from a change in an actuarial assumption that has not been recognized in net periodic benefit cost, after tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 4
-Subparagraph c, d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 19, 24
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The adjustment out of other comprehensive income for the net transition asset or obligation recognized as a component of net periodic benefit cost during the period, after tax.

+ References + Details

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Compensation and Retirement Disclosure [Abstract]
Discount rate	2.40%	5.30%	5.20%
Rate of increased salary levels	1.50%	2.60%	2.00%
Expected long-term rate of return on assets	2.10%	1.60%	1.60%

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Mar. 31, 2012 USD ($)
Expected Benefit Payments
Fiscal Year 2013	$ 1,199
Fiscal Year 2014	1,428
Fiscal Year 2015	1,073
Fiscal Year 2016	1,429
Fiscal Year 2017	1,878
Fiscal Year 2018-2021	$ 4,545

SEGMENT INFORMATION (Revenues from External Customers) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Apr. 02, 2011	Jan. 01, 2011	Oct. 02, 2010	Jul. 03, 2010	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Revenue from External Customer [Line Items]
Net revenues	$ 186,670	$ 191,160	$ 179,445	$ 170,569	$ 170,033	$ 176,789	$ 166,833	$ 163,039	$ 727,844	$ 676,694	$ 645,430
Reportable Segment [Member]
Revenue from External Customer [Line Items]
Net revenues									594,933	551,836	555,226
Reportable Segment [Member] \| Plasma Disposables [Member]
Revenue from External Customer [Line Items]
Net revenues									258,061	227,209	232,378
Reportable Segment [Member] \| Blood Center [Member]
Revenue from External Customer [Line Items]
Net revenues									215,980	203,079	199,057
Reportable Segment [Member] \| Platelet [Member]
Revenue from External Customer [Line Items]
Net revenues									167,946	156,251	151,026
Reportable Segment [Member] \| Red Cell [Member]
Revenue from External Customer [Line Items]
Net revenues									48,034	46,828	48,031
Reportable Segment [Member] \| Hospital [Member]
Revenue from External Customer [Line Items]
Net revenues									120,892	121,548	123,791
Reportable Segment [Member] \| Surgical [Member]
Revenue from External Customer [Line Items]
Net revenues									66,619	66,503	69,942
Reportable Segment [Member] \| OrthoPAT [Member]
Revenue from External Customer [Line Items]
Net revenues									31,186	35,631	37,079
Reportable Segment [Member] \| Diagnostics [Member]
Revenue from External Customer [Line Items]
Net revenues									23,087	19,414	16,770
Reportable Segment [Member] \| Software Solutions [Member]
Revenue from External Customer [Line Items]
Net revenues									70,557	66,876	35,919
Reportable Segment [Member] \| Equipment and Other [Member]
Revenue from External Customer [Line Items]
Net revenues									$ 62,354	$ 57,982	$ 54,285

SEGMENT INFORMATION (Enterprise Wide Disclosures about Product and Services) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	$ 727,844	$ 676,694	$ 645,430
Total Assets	911,135	833,264	764,305
Long-Lived Assets	373,264	372,684	364,361
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	352,160	316,447	301,774
Total Assets	634,171	582,733	487,955
Long-Lived Assets	305,370	305,305	313,241
Other North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	512	908	2,191
Total Assets	15,365	15,903	22,941
Long-Lived Assets	12,796	12,715	16,800
Total North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	352,672	317,355	303,965
Total Assets	649,536	598,636	510,896
Long-Lived Assets	318,166	318,020	330,041
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	124,381	110,263	109,573
Total Assets	50,509	47,156	42,438
Long-Lived Assets	13,128	12,391	11,230
Other Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	67,223	61,594	51,324
Total Assets	27,353	18,164	20,928
Long-Lived Assets	3,961	4,181	3,805
Total Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	191,604	171,857	160,897
Total Assets	77,862	65,320	63,366
Long-Lived Assets	17,089	16,572	15,035
Total Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	183,568	187,482	180,568
Total Assets	183,737	169,308	190,043
Long-Lived Assets	$ 38,009	$ 38,092	$ 19,285

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred	$ 5,858	$ 3,684	$ 24,284
Asset write down	0	0	15,686
Stock Compensation Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred		1,700
Other exit & termination costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred			15,686
Asset write down			15,686
Employee-related costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred	4,112	3,595	8,598
Asset write down	$ 0	0	$ 0
Global Med Technologies, Inc. [Member] \| Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred		$ 2,100

- Definition

Amount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.

+ References + Details

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 3,671	$ 9,761	$ 2,849
Cost Incurred	5,858	3,684	24,284
Payments	(7,535)	(10,574)	(1,686)
Asset Write down	0	0	(15,686)
Ending Balance	1,994	3,671	9,761
Employee-related costs
Restructuring Reserve [Roll Forward]
Beginning Balance	2,782	9,761	2,729
Cost Incurred	4,112	3,595	8,598
Payments	(5,433)	(10,574)	(1,566)
Asset Write down	0	0	0
Ending Balance	1,461	2,782	9,761
Facility-related costs
Restructuring Reserve [Roll Forward]
Beginning Balance	889	0	42
Cost Incurred	1,746	89	0
Payments	(2,102)	0	(42)
Asset Write down	0	0	0
Ending Balance	$ 533	889	0
Other exit & termination costs
Restructuring Reserve [Roll Forward]
Beginning Balance		$ 0	78
Cost Incurred			15,686
Payments			(78)
Asset Write down			(15,686)
Ending Balance			$ 0

- Definition

+ References + Details

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) $ in Millions	2 Months Ended	12 Months Ended
	May 17, 2012 USD ($) Projects	Mar. 31, 2012 USD ($)	Apr. 02, 2011 USD ($)	Apr. 03, 2010 USD ($)
Schedule of Capitalization [Line Items]
Capitalization of costs incurred for acquisition of the software license and related software development costs		$ 3.6	$ 2.8
Capitalized software development costs for ongoing initiatives		6.1	6.9	$ 4.7
Software costs capitalized, net		19.5	13.4
Total costs capitalized related to in process software development initiatives		15.4	13.4
Interest costs capitalized		$ 0.2	0.1
Capitalized software impairment			12.2
Intangible asset impairment			$ 3.5
In Process Project Placed Into Service [Member]
Schedule of Capitalization [Line Items]
Capitalized software development costs for ongoing initiatives	$ 4.1
Number of in-process projects \| Projects	1

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Apr. 02, 2011	Jan. 01, 2011	Oct. 02, 2010	Jul. 03, 2010	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Quarterly Financial Data [Abstract]
Net revenues	$ 186,670	$ 191,160	$ 179,445	$ 170,569	$ 170,033	$ 176,789	$ 166,833	$ 163,039	$ 727,844	$ 676,694	$ 645,430
Gross profit	94,612	95,931	89,949	88,748	87,501	93,490	87,755	86,463	369,240	355,209	337,481
Operating income	20,960	25,324	18,566	23,908	28,895	28,559	28,905	24,189	88,758	110,548	83,281
Net income	$ 17,805	$ 18,254	$ 13,880	$ 16,947	$ 20,989	$ 19,734	$ 21,338	$ 17,918	$ 66,886	$ 79,980	$ 58,370
Share data:
Basic income per share (in dollars per share)	$ 0.71	$ 0.73	$ 0.55	$ 0.66	$ 0.82	$ 0.79	$ 0.86	$ 0.71	$ 2.64	$ 3.19	$ 2.29
Diluted income per share (in dollars per share)	$ 0.69	$ 0.72	$ 0.54	$ 0.65	$ 0.81	$ 0.77	$ 0.85	$ 0.70	$ 2.59	$ 3.12	$ 2.24

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

SUBSEQUENT EVENTS (UNAUDITED) (Narrative) (Details) $ in Millions	Apr. 29, 2012 USD ($)
Pall Corporation Purcahse Agreement [Member] \| Acquisition [Member]
Subsequent Event [Line Items]
Business acquisition, cash paid	$ 551
Contingent consideration	15
Contract termination fee	17
Pall Corporation Purcahse Agreement [Member] \| Financing [Member]
Subsequent Event [Line Items]
Principal amount of term loans	475
Principal amount of credit facility	50
Hemerus Medical, LLC [Member] \| Acquisition [Member]
Subsequent Event [Line Items]
Contingent consideration	$ 27

VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 1,799	$ 2,554	$ 2,312
Charged to Costs and Expenses	(39)	343	363
Write-Offs (Net of Recoveries)	(280)	(1,098)	(121)
Balance at End of Period	$ 1,480	$ 1,799	$ 2,554